{"protocolSection": {"identificationModule": {"nctId": "NCT01126580", "orgStudyIdInfo": {"id": "11375"}, "secondaryIdInfos": [{"id": "H9X-MC-GBDC", "type": "OTHER", "domain": "Eli Lilly and Company"}, {"id": "CTRI/2010/091/003036", "type": "REGISTRY", "domain": "Clinical Trials Register India"}], "organization": {"fullName": "Eli Lilly and Company", "class": "INDUSTRY"}, "briefTitle": "A Study in Participants With Type 2 Diabetes Mellitus (AWARD-3)", "officialTitle": "The Impact of LY2189265 Versus Metformin on Glycemic Control in Early Type 2 Diabetes Mellitus (AWARD-3: Assessment of Weekly AdministRation of LY2189265 in Diabetes-3)"}, "statusModule": {"statusVerifiedDate": "2015-01", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2010-05"}, "primaryCompletionDateStruct": {"date": "2011-11", "type": "ACTUAL"}, "completionDateStruct": {"date": "2012-06", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-05-18", "studyFirstSubmitQcDate": "2010-05-18", "studyFirstPostDateStruct": {"date": "2010-05-19", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2014-10-03", "resultsFirstSubmitQcDate": "2015-01-15", "resultsFirstPostDateStruct": {"date": "2015-01-16", "type": "ESTIMATED"}, "dispFirstSubmitDate": "2012-05-24", "dispFirstSubmitQcDate": "2012-05-24", "dispFirstPostDateStruct": {"date": "2012-06-01", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-01-15", "lastUpdatePostDateStruct": {"date": "2015-01-16", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Eli Lilly and Company", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to determine if LY2189265 is safe and effective in reducing glycosylated hemoglobin (HbA1c) as compared to metformin in participants with Type 2 Diabetes.", "detailedDescription": "The term rescue therapy in this trial was defined primarily as additional nontrial antidiabetic medication for the management of severe, persistent hyperglycemia or alternative antidiabetic medication following study drug discontinuation. For efficacy analyses, participants who received rescue medication were included in the analysis population, but only measurements obtained prior to taking rescue therapy were included in the efficacy analysis. For safety analyses, with the exception of hypoglycemia outcomes, all measurements including those obtained after taking rescue therapy were included in the analysis."}, "conditionsModule": {"conditions": ["Diabetes Mellitus, Type 2"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 807, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "1.5 mg LY2189265", "type": "EXPERIMENTAL", "description": "LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: 1 tablet per day, orally, for Week 1; 2 tablets per day, orally, for Week 2; 3 tablets per day, orally, for Week 3; 4 or at least 3 tablets, orally, for Weeks 4 through Week 52", "interventionNames": ["Drug: LY2189265", "Drug: Placebo (oral)"]}, {"label": "0.75 mg LY2189265", "type": "EXPERIMENTAL", "description": "LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: 1 tablet per day, orally, for Week 1; 2 tablets per day, orally, for Week 2; 3 tablets per day, orally, for Week 3; 4 or at least 3 tablets, orally, for Weeks 4 through Week 52", "interventionNames": ["Drug: LY2189265", "Drug: Placebo (oral)"]}, {"label": "Metformin", "type": "ACTIVE_COMPARATOR", "description": "Metformin: 500 milligrams per day (mg/day), orally, for Week 1; 1000 mg/day, orally, for Week 2; 1500 mg/day, orally, for Week 3; 2000 or at least 1500 mg/day, orally, for Weeks 4 through Week 52\n\nPlacebo: subcutaneously (SC), once weekly for 52 weeks", "interventionNames": ["Drug: Metformin", "Drug: Placebo (subcutaneous)"]}], "interventions": [{"type": "DRUG", "name": "Metformin", "armGroupLabels": ["Metformin"]}, {"type": "DRUG", "name": "LY2189265", "armGroupLabels": ["0.75 mg LY2189265", "1.5 mg LY2189265"], "otherNames": ["Dulaglutide"]}, {"type": "DRUG", "name": "Placebo (oral)", "armGroupLabels": ["0.75 mg LY2189265", "1.5 mg LY2189265"]}, {"type": "DRUG", "name": "Placebo (subcutaneous)", "armGroupLabels": ["Metformin"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline to 26-week Endpoint in Glycosylated Hemoglobin (HbA1c)", "description": "Least Squares (LS) means were calculated using analysis of covariance (ANCOVA) with country, treatment, and prior medication group (previous oral antihyperglycemic medication \\[OAM\\] versus no previous OAM) as fixed effects and baseline HbA1c as a covariate.", "timeFrame": "Baseline, 26 weeks"}], "secondaryOutcomes": [{"measure": "Change From Baseline to 52-week Endpoint in Glycosylated Hemoglobin (HbA1c)", "description": "Least Squares (LS) means were calculated using analysis of covariance (ANCOVA) with country, treatment, and prior medication group (previous oral antihyperglycemic medication \\[OAM\\] versus no previous OAM) as fixed effects and baseline HbA1c as a covariate.", "timeFrame": "Baseline, 52 weeks"}, {"measure": "Percentage of Participants Achieving a Glycosylated Hemoglobin (HbA1c) of Less Than 7% and Less Than or Equal to 6.5% at 26 and 52 Weeks", "description": "The percentage of participants achieving HbA1c level less than 7.0% and less than or equal to 6.5% was analyzed with a logistic regression model with baseline, prior medication group, and treatment as factors included in the model.", "timeFrame": "26 weeks and 52 weeks"}, {"measure": "Change From Baseline to 26 and 52 Weeks in Fasting Blood Glucose", "description": "Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, prior medication group, visit, and treatment-by-visit interaction as fixed effects, baseline fasting blood glucose as a covariate, and participant as a random effect.", "timeFrame": "Baseline, 26 weeks, and 52 weeks"}, {"measure": "Change From Baseline to 26 and 52 Weeks in Daily Mean Blood Glucose Values From the 8-point Self-monitored Blood Glucose (SMBG) Profiles", "description": "The SMBG data were collected at the following 8 time points: pre-morning meal; 2 hours post-morning meal; pre-midday meal; 2 hours post-midday meal; pre-evening; 2 hours post-evening meal; bedtime; and 3AM or 5 hours after bedtime. Least Squares (LS) means of the mean of the 8 time points (daily mean) were calculated using analysis of covariance (ANCOVA) with country, treatment, and prior medication group as fixed effects and baseline daily mean as a covariate.", "timeFrame": "Baseline, 26 weeks, and 52 weeks"}, {"measure": "Change From Baseline to 26 and 52 Weeks in Body Weight", "description": "Least Squares (LS) means were calculated using analysis of covariance (ANCOVA) with country, treatment, and prior medication group as fixed effects and baseline body weight as a covariate.", "timeFrame": "Baseline, 26 weeks, and 52 weeks"}, {"measure": "Change From Baseline to 26 and 52 Weeks in Body Mass Index (BMI)", "description": "Body mass index is an estimate of body fat based on body weight divided by height squared. Least Squares (LS) means were calculated using analysis of covariance (ANCOVA) with country, treatment, and prior medication group as fixed effects and baseline BMI as a covariate.", "timeFrame": "Baseline, 26 weeks, and 52 weeks"}, {"measure": "Change From Baseline to 26 and 52 Weeks in Homeostasis Model Assessment of Beta-cell Function", "description": "The homeostatic model assessment (HOMA) quantifies insulin resistance and beta-cell function. HOMA2-B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady-state beta cell function (%B) as a percentage of a normal reference population (normal young adults). HOMA2-S is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin sensitivity (%S) as percentages of a normal reference population (normal young adults). The normal reference populations were set at 100%. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, prior medication group, visit, and treatment-by-visit interaction as fixed effects, baseline HOMA2 as a covariate, and participant as a random effect.", "timeFrame": "Baseline, 26 weeks, and 52 weeks"}, {"measure": "Change From Baseline to 26 and 52 Weeks in the Impact of Weight on Activities of Daily Living (IW-ADL) Score", "description": "The Impact of Weight on Activities of Daily Living (renamed the Ability to Perform Physical Activities of Daily Living \\[APPADL\\]) questionnaire contains 7 items that assess how difficult it is for participants to engage in certain activities considered to be integral to normal daily life, such as walking, standing and climbing stairs. Items are scored on a 5-point numeric rating scale where 5 = \"not at all difficult\" and 1 = \"unable to do\". The individual scores from all 7 items are summed and a single total score is calculated and may range between 7 and 35. A higher score indicates better ability to perform activities of daily living. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusted by treatment, country, prior medication group, gender, and baseline score.", "timeFrame": "Baseline, 26 weeks, and 52 weeks"}, {"measure": "Change From Baseline to 26 and 52 Weeks in the Impact of Weight on Self-Perception (IW-SP) Score", "description": "The Impact of Weight on Self-Perception (IW-SP) questionnaire contains 3 items that assess how often the participants' body weight affects how happy they are with their appearance and how often they feel self-conscious when out in public. Items are scored on a 5-point numeric rating scale where 5 = never and 1 = always. A single total score is calculated by summing the scores for all 3 items. Total score ranges between 3 and 15, where a higher score is indicative of better self-perception. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusted by treatment, country, prior medication group, gender, and baseline score.", "timeFrame": "Baseline, 26 weeks, and 52 weeks"}, {"measure": "Change From Baseline to 26 and 52 Weeks in the Diabetes Treatment Satisfaction Questionnaire (DTSQ) Score, Status Version", "description": "The Diabetes Treatment Satisfaction Questionnaire status version (DTSQs) is used to assess participant treatment satisfaction at each study visit. The questionnaire consists of 8 items, 6 of which (1 and 4 through 8) assess treatment satisfaction. Each item is rated on a 7-point Likert scale. Scores from the 6 treatment satisfaction items are summed to a Total Treatment Satisfaction Score, which ranges from 0 (very dissatisfied) to 36 (very satisfied). Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusted by treatment, country, prior medication group, gender, and baseline score.", "timeFrame": "Baseline, 26 weeks, and 52 weeks"}, {"measure": "Diabetes Treatment Satisfaction Questionnaire (DTSQ) Score, Change Version", "description": "The Diabetes Treatment Satisfaction Questionnaire change (DTSQc) score is used to assess relative change in participant satisfaction from baseline. The questionnaire consists of 8 items, 6 of which (1 and 4 through 8) assess treatment satisfaction. Each item is rated on a 7-point Likert scale. The scores from the 6 treatment satisfaction items are summed to a Total Treatment Satisfaction Score, which ranges from -18 (much less satisfied) to +18 (much more satisfied). Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusted by treatment, country, prior medication group, gender, and baseline score.", "timeFrame": "52 weeks"}, {"measure": "Change From Baseline to 26 and 52 Weeks in the Diabetes Symptoms Checklist Participant-reported Outcome (DSC-r) Score", "description": "The Diabetes Symptoms Checklist-revised (DSC-r) was designed to assess the presence and perceived burden of diabetes-related symptoms. Respondents were to consider troublesomeness of 34 symptoms on a 5-point scale ranging from 5=\"extremely\" to 1=\"not at all.\" For symptoms/side-effects not experienced, the item was scored as 0. Symptoms were grouped into the following subscales: psychology-fatigue, psychology-cognitive, neurology-pain, neurology-sensory, cardiology, ophthalmology, hypoglycemia, and hyperglycemia. Subscale scores were calculated as the sum of the given subscale divided by the total number of items in the scale. Total score was computed from the sum of the 8 subscales and ranged from 0 to 40. Higher scores indicate greater symptom burden. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusted by treatment, country, prior medication group, gender, and baseline score.", "timeFrame": "Baseline, 26 weeks, and 52 weeks"}, {"measure": "Number of Participants With Treatment Emergent Adverse Events at 26 and 52 Weeks", "description": "A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with one or more TEAE is summarized cumulatively at 26 and 52 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.", "timeFrame": "26 weeks and 52 weeks"}, {"measure": "Change From Baseline to 26 and 52 Weeks in Electrocardiogram Parameters, Fridericia Corrected QT (QTcF) Interval and PR Interval", "description": "The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR\\^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. PR is the interval between the P wave and the QRS complex. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, prior medication group, visit, and treatment-by-visit interaction as fixed effects, baseline interval as a covariate, and participant as a random effect.", "timeFrame": "Baseline, 26 weeks, and 52 weeks"}, {"measure": "Change From Baseline to 26 and 52 Weeks in Electrocardiogram Parameters, Heart Rate", "description": "Electrocardiogram (ECG) heart rate was measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, prior medication group, visit, and treatment-by-visit interaction as fixed effects and baseline interval as a covariate.", "timeFrame": "Baseline, 26 weeks, and 52 weeks"}, {"measure": "Change From Baseline to 26 and 52 Weeks in Pulse Rate", "description": "Sitting pulse rate was measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, prior medication group, visit, and treatment-by-visit interaction as fixed effects, baseline interval as a covariate, and participant as a random effect.", "timeFrame": "Baseline, 26 weeks, and 52 weeks"}, {"measure": "Change From Baseline to 26 and 52 Weeks in Blood Pressure", "description": "Sitting systolic blood pressure (SBP) and sitting diastolic blood pressure (DBP) were measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, prior medication group, visit, and treatment-by-visit interaction as fixed effects, baseline interval as a covariate, and participant as a random effect.", "timeFrame": "Baseline, 26 weeks, and 52 weeks"}, {"measure": "Percent Change From Baseline to 26 and 52 Weeks in Total Cholesterol", "description": "Percent changes in total cholesterol were assessed using analysis of variance (ANOVA) on the rank-transformed data with only treatment included in the model.", "timeFrame": "Baseline, 26 weeks, and 52 weeks"}, {"measure": "Percentage Change From Baseline to 26 and 52 Weeks in High Density Lipoprotein Cholesterol (HDL-C)", "description": "Percentage changes in HDL-C were assessed using analysis of variance (ANOVA) on the rank-transformed data with only treatment included in the model.", "timeFrame": "Baseline, 26 weeks, and 52 weeks"}, {"measure": "Percentage Change From Baseline to 26 and 52 Weeks in Low Density Lipoprotein Cholesterol (LDL-C)", "description": "Percentage changes in LDL-C were assessed using analysis of variance (ANOVA) on the rank-transformed data with only treatment included in the model.", "timeFrame": "Baseline, 26 weeks, and 52 weeks"}, {"measure": "Percentage Change From Baseline to 26 and 52 Weeks in Triglycerides", "description": "Percentage changes in triglycerides were assessed using analysis of variance (ANOVA) on the rank-transformed data with only treatment included in the model.", "timeFrame": "Baseline, 26 weeks, and 52 weeks"}, {"measure": "Change From Baseline to 26 and 52 Weeks in Pancreatic Enzymes", "description": "Amylase (total and pancreas-derived \\[PD\\]) and lipase concentrations were measured.", "timeFrame": "Baseline, 26 weeks, and 52 weeks"}, {"measure": "Change From Baseline to 26 and 52 Weeks in Serum Calcitonin", "timeFrame": "Baseline, 26 weeks, and 52 weeks"}, {"measure": "Number of Participants With Treatment Emergent Anti-LY2189265 Antibodies", "description": "A participant was considered to have treatment emergent LY2189265 anti-drug antibodies (ADA) if the participant had at least one titer that was treatment-emergent relative to baseline, defined as a 4-fold or greater increase in titer from baseline measurement. The total number of treatment emergent ADA was not analyzed at 26 weeks.", "timeFrame": "Baseline through 52 weeks"}, {"measure": "Number of Self-reported Hypoglycemic Events at 26 and 52 Weeks", "description": "Hypoglycemic events were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of less than or equal to 70 milligrams per deciliter \\[mg/dL\\]), or asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of less than or equal to 70 mg/dL). A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.", "timeFrame": "Baseline through 26 weeks and 52 weeks"}, {"measure": "Rate of Self-reported Hypoglycemic Events at 52 Weeks", "description": "Hypoglycemic events were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of less than or equal to 70 milligrams per deciliter \\[mg/dL\\]), or asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of less than or equal to 70 mg/dL). The 1-year adjusted rate of hypoglycemic events is summarized cumulatively at 52 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.", "timeFrame": "Baseline through 52 weeks"}, {"measure": "Number of Participants With Adjudicated Pancreatitis at 52 Weeks Plus 30-day Follow up", "description": "The number of participants with pancreatitis confirmed by adjudication is summarized cumulatively at 52 weeks plus 30-day follow up. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.", "timeFrame": "Baseline through 52 weeks plus 30-day follow up"}, {"measure": "Number of Participants With Adjudicated Cardiovascular Events at 52 Weeks Plus 30-day Follow up", "description": "Information on cardiovascular (CV) risk factors was collected at baseline. Data on any new CV event was prospectively collected using a CV event electronic case report form. Deaths and nonfatal cardiovascular adverse events (AEs) were adjudicated by an external committee of physicians with cardiology expertise. Nonfatal cardiovascular AEs to be adjudicated included myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions, and cerebrovascular events, including cerebrovascular accident (stroke) and transient ischemic attack. The number of participants with CV events confirmed by adjudication is summarized cumulatively at 52 weeks plus 30-day follow up. Serious and all other non-serious adverse events regardless of causality are summarized in the Reported Adverse Events module.", "timeFrame": "Baseline through 52 weeks plus 30-day follow up"}, {"measure": "Measurement of LY2189265 Drug Concentration for Pharmacokinetics: Area Under the Concentration Curve (AUC)", "description": "Evaluable pharmacokinetic concentrations from the 4-week, 13-week, 26-week, and 52-week timepoints were combined and utilized in a population approach to determine the population mean estimate and standard deviation at steady-state.", "timeFrame": "4 weeks, 13 weeks, 26 weeks, and 52 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Have type 2 diabetes for greater than or equal to 3 months and less than or equal to 5 years based on the disease diagnostic criteria (refer to the World Health Organization's \\[WHO\\] Classification of Diabetes).\n* Are treatment-na\u00efve, not optimally controlled with diet and exercise alone, or are taking 1 oral antihyperglycemic medication (OAM) as monotherapy (excluding thiazolidinediones). For those on 1 OAM, the dose must be less than or equal to 50% the maximum authorized per local label.\n* Are able and willing to tolerate a minimum dose of 1500 milligrams per day (mg/day) or up to 2000 mg/day of metformin.\n* Have glycosylated hemoglobin (HbA1c) greater than or equal to 6.5% to less than or equal to 9.5%.\n* Females of childbearing potential (not surgically sterilized and between menarche and 1-year postmenopausal) must: a) test negative for pregnancy at screening based on a serum pregnancy test, and b) agree to use a reliable method of birth control during the study and for 1 month following the last dose of study drug; or c) not be breastfeeding.\n* Have a stable weight (plus or minus 5%) greater than or equal to 3 months prior to screening.\n* Have a body mass index (BMI) between 23 and 45 kilograms per square meter (kg/m\\^2), inclusive.\n* Are well-motivated, capable, and willing to: a) perform self-monitored blood glucose (SMBG) testing; b) learn how to self-inject treatment (LY2189265 or placebo) and c) maintain a study diary.\n\nExclusion Criteria:\n\n* Have type 1 diabetes mellitus.\n* Are being or have been treated with any of the following medications: a) chronically treated with insulin for the treatment of diabetes in the past; however, a short-term use of insulin more than 3 months prior to screening is allowable, b) glucagon-like peptide 1 (GLP-1) analogs within 3 months prior to this screening, c) drugs to cause weight loss within 3 months prior to screening, d) thiazolidinediones (TZDs) within 3 months prior to screening, e) chronically treated (greater than or equal to 14 days) with an oral glucocorticoid or have received this type of therapy within 4 weeks prior to screening, or f) illegal drugs.\n* Have had 1 or more cases of uncontrolled diabetes that required hospitalization in the 6 months prior to screening.\n* Have stomach problems, have chronically taken medication to increase movement in the digestive tract or slow down the emptying of the digestive tract, or have had gastric bypass (bariatric) surgery.\n* Have had problems with the heart or brain in the past 2 months prior to screening, such as a heart attack, chest pain, heart failure, heart bypass operation, angioplasty or stent insertion, a heart rhythm problem, or a stroke.\n* Have a serum creatinine result which shows a greater than or equal to 1.5 milligrams per deciliter (mg/dL) for men or greater than or equal to 1.4 mg/dL for women.\n* Have a problem with the liver or pancreas.\n* Have a creatinine clearance result which shows less than 60 milliliters per minute (mL/min), evidence of a significant active, uncontrolled endocrine (hormone), or active autoimmune abnormality.\n* Have a serum calcitonin test which shows greater than or equal to 20 picograms per milliliter (pcg/mL) at the time of screening.\n* Have a family history of medullary C-cell hyperplasia or endocrine neoplasia type 2A or type 2B.\n* Have cancer (except for skin cancer) or have been in remission from cancer for less than 5 years.\n* Have had an organ transplant except for corneal transplant.\n* Have received treatment within the last 30 days with a drug which has not been regulatory approved.\n* Have participated in a medical, surgical, or pharmaceutical study where these types of procedures were performed within 30 days prior to screening.\n* Have any condition that is a contraindication to or would interfere with medications provided for this study to treat diabetes.\n* Have a blood disorder that would interfere with the drawing of blood glucose measurements or lab samples.\n* Have previously participated or signed an informed consent document for this same type of study and study drug.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", "affiliation": "Eli Lilly and Company", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Huntsville", "state": "Alabama", "zip": "35801", "country": "United States", "geoPoint": {"lat": 34.7304, "lon": -86.58594}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Phoenix", "state": "Arizona", "zip": "85018", "country": "United States", "geoPoint": {"lat": 33.44838, "lon": -112.07404}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Buena Park", "state": "California", "zip": "90620", "country": "United States", "geoPoint": {"lat": 33.86751, "lon": -117.99812}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Burbank", "state": "California", "zip": "91505", "country": "United States", "geoPoint": {"lat": 34.18084, "lon": -118.30897}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Redlands", "state": "California", "zip": "92374", "country": "United States", "geoPoint": {"lat": 34.05557, "lon": -117.18254}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "San Mateo", "state": "California", "zip": "94401", "country": "United States", "geoPoint": {"lat": 37.56299, "lon": -122.32553}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Fort Lauderdale", "state": "Florida", "zip": "33316", "country": "United States", "geoPoint": {"lat": 26.12231, "lon": -80.14338}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Orlando", "state": "Florida", "zip": "32822", "country": "United States", "geoPoint": {"lat": 28.53834, "lon": -81.37924}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Atlanta", "state": "Georgia", "zip": "30303", "country": "United States", "geoPoint": {"lat": 33.749, "lon": -84.38798}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Idaho Falls", "state": "Idaho", "zip": "83404", "country": "United States", "geoPoint": {"lat": 43.46658, "lon": -112.03414}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Gurnee", "state": "Illinois", "zip": "60031", "country": "United States", "geoPoint": {"lat": 42.3703, "lon": -87.90202}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Springfield", "state": "Illinois", "zip": "62704", "country": "United States", "geoPoint": {"lat": 39.80172, "lon": -89.64371}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Topeka", "state": "Kansas", "zip": "66606", "country": "United States", "geoPoint": {"lat": 39.04833, "lon": -95.67804}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Louisville", "state": "Kentucky", "zip": "40217", "country": "United States", "geoPoint": {"lat": 38.25424, "lon": -85.75941}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Southfield", "state": "Michigan", "zip": "48075", "country": "United States", "geoPoint": {"lat": 42.47337, "lon": -83.22187}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Nashua", "state": "New Hampshire", "zip": "03063", "country": "United States", "geoPoint": {"lat": 42.76537, "lon": -71.46757}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Rochester", "state": "New York", "zip": "14609", "country": "United States", "geoPoint": {"lat": 43.15478, "lon": -77.61556}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Raleigh", "state": "North Carolina", "zip": "27609", "country": "United States", "geoPoint": {"lat": 35.7721, "lon": -78.63861}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Eugene", "state": "Oregon", "zip": "97404", "country": "United States", "geoPoint": {"lat": 44.05207, "lon": -123.08675}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Beaver", "state": "Pennsylvania", "zip": "15009", "country": "United States", "geoPoint": {"lat": 40.69534, "lon": -80.30478}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Johnstown", "state": "Pennsylvania", "zip": "15905", "country": "United States", "geoPoint": {"lat": 40.32674, "lon": -78.92197}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Levittown", "state": "Pennsylvania", "zip": "19056", "country": "United States", "geoPoint": {"lat": 40.15511, "lon": -74.82877}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Austin", "state": "Texas", "zip": "78749", "country": "United States", "geoPoint": {"lat": 30.26715, "lon": -97.74306}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Georgetown", "state": "Texas", "zip": "78626", "country": "United States", "geoPoint": {"lat": 30.63269, "lon": -97.67723}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Richmond", "state": "Virginia", "zip": "23233", "country": "United States", "geoPoint": {"lat": 37.55376, "lon": -77.46026}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Olympia", "state": "Washington", "zip": "98502", "country": "United States", "geoPoint": {"lat": 47.03787, "lon": -122.9007}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Selah", "state": "Washington", "zip": "98942", "country": "United States", "geoPoint": {"lat": 46.65402, "lon": -120.53007}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Spokane", "state": "Washington", "zip": "99208", "country": "United States", "geoPoint": {"lat": 47.65966, "lon": -117.42908}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Buenos Aires", "zip": "C1188AAF", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "San Isidro", "zip": "B1642DCD", "country": "Argentina", "geoPoint": {"lat": -34.4721, "lon": -58.52708}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Fortaleza", "zip": "60430-350", "country": "Brazil", "geoPoint": {"lat": -3.71722, "lon": -38.54306}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "S\u00e3o Paulo", "zip": "04020-041", "country": "Brazil", "geoPoint": {"lat": -23.5475, "lon": -46.63611}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Kelowna", "state": "British Columbia", "zip": "V1Y 1Z9", "country": "Canada", "geoPoint": {"lat": 49.88307, "lon": -119.48568}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Vancouver", "state": "British Columbia", "zip": "V5Z 3J5", "country": "Canada", "geoPoint": {"lat": 49.24966, "lon": -123.11934}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Winnipeg", "state": "Manitoba", "zip": "R2V 4W3", "country": "Canada", "geoPoint": {"lat": 49.8844, "lon": -97.14704}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Halifax", "state": "Nova Scotia", "zip": "B3H 1V7", "country": "Canada", "geoPoint": {"lat": 44.64533, "lon": -63.57239}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Toronto", "state": "Ontario", "zip": "M9W 4L6", "country": "Canada", "geoPoint": {"lat": 43.70011, "lon": -79.4163}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Sherbrooke", "state": "Quebec", "zip": "J1H1Z1", "country": "Canada", "geoPoint": {"lat": 45.40008, "lon": -71.89908}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Dubrovnik", "zip": "20000", "country": "Croatia", "geoPoint": {"lat": 42.64807, "lon": 18.09216}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Osijek", "zip": "31000", "country": "Croatia", "geoPoint": {"lat": 45.55111, "lon": 18.69389}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Slavonski Brod", "zip": "35000", "country": "Croatia", "geoPoint": {"lat": 45.16028, "lon": 18.01556}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Zagreb", "zip": "10000", "country": "Croatia", "geoPoint": {"lat": 45.81444, "lon": 15.97798}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Beroun", "zip": "26601", "country": "Czech Republic", "geoPoint": {"lat": 49.96382, "lon": 14.072}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Novy Jicin", "zip": "74101", "country": "Czech Republic", "geoPoint": {"lat": 49.59438, "lon": 18.01028}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Prague", "zip": "149 00", "country": "Czech Republic", "geoPoint": {"lat": 50.08804, "lon": 14.42076}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Nurmijarvi", "zip": "01900", "country": "Finland", "geoPoint": {"lat": 60.46407, "lon": 24.8073}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Oulu", "zip": "90100", "country": "Finland", "geoPoint": {"lat": 65.01236, "lon": 25.46816}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "La Bouexiere", "zip": "35340", "country": "France", "geoPoint": {"lat": 48.18333, "lon": -1.43333}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Murs Erigne", "zip": "49610", "country": "France", "geoPoint": {"lat": 47.4, "lon": -0.55}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Nantes", "zip": "44300", "country": "France", "geoPoint": {"lat": 47.21725, "lon": -1.55336}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Vieux Conde", "zip": "59690", "country": "France", "geoPoint": {"lat": 50.45944, "lon": 3.56738}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Gebhardshain", "zip": "57580", "country": "Germany", "geoPoint": {"lat": 50.75, "lon": 7.81667}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Mainz", "zip": "55116", "country": "Germany", "geoPoint": {"lat": 49.98419, "lon": 8.2791}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "M\u00fcnster", "zip": "48145", "country": "Germany", "geoPoint": {"lat": 51.96236, "lon": 7.62571}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Neunkirchen", "zip": "66539", "country": "Germany", "geoPoint": {"lat": 49.34449, "lon": 7.18045}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Potsdam", "zip": "14469", "country": "Germany", "geoPoint": {"lat": 52.39886, "lon": 13.06566}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Bangalore", "zip": "560003", "country": "India", "geoPoint": {"lat": 12.97194, "lon": 77.59369}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Chennai", "zip": "600029", "country": "India", "geoPoint": {"lat": 13.08784, "lon": 80.27847}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Mumbai", "zip": "400053", "country": "India", "geoPoint": {"lat": 19.07283, "lon": 72.88261}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Nagpur", "zip": "440020", "country": "India", "geoPoint": {"lat": 21.14631, "lon": 79.08491}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Bucheon", "zip": "420-717", "country": "Korea, Republic of", "geoPoint": {"lat": 37.49889, "lon": 126.78306}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Seoul", "zip": "136 705", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Suwon-City", "zip": "442-723", "country": "Korea, Republic of", "geoPoint": {"lat": 37.29111, "lon": 127.00889}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Mexico City", "zip": "6700", "country": "Mexico", "geoPoint": {"lat": 19.42847, "lon": -99.12766}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Monterrey", "zip": "64461", "country": "Mexico", "geoPoint": {"lat": 25.67507, "lon": -100.31847}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Tampico", "zip": "89000", "country": "Mexico", "geoPoint": {"lat": 22.26695, "lon": -97.86815}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Lodz", "zip": "90-242", "country": "Poland", "geoPoint": {"lat": 51.75, "lon": 19.46667}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Warsaw", "zip": "02-091", "country": "Poland", "geoPoint": {"lat": 52.22977, "lon": 21.01178}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Wroclaw", "zip": "50-349", "country": "Poland", "geoPoint": {"lat": 51.1, "lon": 17.03333}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Carolina", "zip": "00983", "country": "Puerto Rico", "geoPoint": {"lat": 18.38078, "lon": -65.95739}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Manati", "zip": "00674", "country": "Puerto Rico", "geoPoint": {"lat": 18.42745, "lon": -66.49212}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "San Juan", "zip": "00987", "country": "Puerto Rico", "geoPoint": {"lat": 18.46633, "lon": -66.10572}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Bucharest", "zip": "020359", "country": "Romania", "geoPoint": {"lat": 44.43225, "lon": 26.10626}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Cluj-Napoca", "zip": "400006", "country": "Romania", "geoPoint": {"lat": 46.76667, "lon": 23.6}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Galati", "zip": "800587", "country": "Romania", "geoPoint": {"lat": 45.45, "lon": 28.05}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Resita", "zip": "320076", "country": "Romania", "geoPoint": {"lat": 45.30083, "lon": 21.88917}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Banska Bystrica", "zip": "97405", "country": "Slovakia", "geoPoint": {"lat": 48.73946, "lon": 19.15349}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Bratislava", "zip": "821 03", "country": "Slovakia", "geoPoint": {"lat": 48.14816, "lon": 17.10674}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Trebisov", "zip": "07501", "country": "Slovakia", "geoPoint": {"lat": 48.62858, "lon": 21.71954}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Halfway House", "zip": "1685", "country": "South Africa", "geoPoint": {"lat": -26.00526, "lon": 28.12637}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Kempton Park", "zip": "1619", "country": "South Africa", "geoPoint": {"lat": -26.10859, "lon": 28.2377}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Somerset West", "zip": "7130", "country": "South Africa", "geoPoint": {"lat": -34.08401, "lon": 18.82113}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Begonte", "zip": "27373", "country": "Spain", "geoPoint": {"lat": 43.15121, "lon": -7.68643}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Granada", "zip": "18012", "country": "Spain", "geoPoint": {"lat": 37.18817, "lon": -3.60667}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Seville", "zip": "41003", "country": "Spain", "geoPoint": {"lat": 37.38283, "lon": -5.97317}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Penzance", "state": "Cornwall", "zip": "TR19 7HX", "country": "United Kingdom", "geoPoint": {"lat": 50.11861, "lon": -5.53715}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Durham", "state": "County Durham", "zip": "DH1 2QW", "country": "United Kingdom", "geoPoint": {"lat": 54.77676, "lon": -1.57566}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "London", "state": "Greater London", "zip": "W9 1SP", "country": "United Kingdom", "geoPoint": {"lat": 51.50853, "lon": -0.12574}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Cleveleys", "state": "Lancashire", "zip": "FY5 3LF", "country": "United Kingdom", "geoPoint": {"lat": 53.8775, "lon": -3.03987}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Crawley", "zip": "RH10 7DX", "country": "United Kingdom", "geoPoint": {"lat": 51.11303, "lon": -0.18312}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Nottingham", "zip": "NG3 7DQ", "country": "United Kingdom", "geoPoint": {"lat": 52.9536, "lon": -1.15047}}]}, "referencesModule": {"references": [{"pmid": "32501595", "type": "DERIVED", "citation": "Gnesin F, Thuesen ACB, Kahler LKA, Madsbad S, Hemmingsen B. Metformin monotherapy for adults with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2020 Jun 5;6(6):CD012906. doi: 10.1002/14651858.CD012906.pub2."}, {"pmid": "27161178", "type": "DERIVED", "citation": "Boustani MA, Pittman I 4th, Yu M, Thieu VT, Varnado OJ, Juneja R. Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged >/=65 and <65 years. Diabetes Obes Metab. 2016 Aug;18(8):820-8. doi: 10.1111/dom.12687. Epub 2016 Jun 7."}, {"pmid": "26691396", "type": "DERIVED", "citation": "Yu M, Van Brunt K, Varnado OJ, Boye KS. Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes Obes Metab. 2016 Apr;18(4):419-24. doi: 10.1111/dom.12624. Epub 2016 Feb 4."}, {"pmid": "24842985", "type": "DERIVED", "citation": "Umpierrez G, Tofe Povedano S, Perez Manghi F, Shurzinske L, Pechtner V. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care. 2014 Aug;37(8):2168-76. doi: 10.2337/dc13-2759. Epub 2014 May 19."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "1.5 mg LY2189265", "description": "LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}, {"id": "FG001", "title": "0.75 mg LY2189265", "description": "LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}, {"id": "FG002", "title": "Metformin", "description": "Metformin: 2000 milligrams per day (mg/day) or at least 1500 mg/day, orally, for 52 weeks\n\nPlacebo: subcutaneously (SC), once weekly for 52 weeks"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "269"}, {"groupId": "FG001", "numSubjects": "270"}, {"groupId": "FG002", "numSubjects": "268"}]}, {"type": "Received at Least 1 Dose of Study Drug", "achievements": [{"groupId": "FG000", "numSubjects": "269"}, {"groupId": "FG001", "numSubjects": "270"}, {"groupId": "FG002", "numSubjects": "268"}]}, {"type": "Completed 26 Weeks", "achievements": [{"groupId": "FG000", "numSubjects": "233"}, {"groupId": "FG001", "numSubjects": "242"}, {"groupId": "FG002", "numSubjects": "226"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "220"}, {"groupId": "FG001", "numSubjects": "218"}, {"groupId": "FG002", "numSubjects": "213"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "49"}, {"groupId": "FG001", "numSubjects": "52"}, {"groupId": "FG002", "numSubjects": "55"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "14"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "12"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "19"}, {"groupId": "FG002", "numSubjects": "14"}]}, {"type": "Sponsor Decision", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "7"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "2"}]}, {"type": "Entry Criteria Not Met", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "2"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "4"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "2"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "15"}, {"groupId": "FG001", "numSubjects": "13"}, {"groupId": "FG002", "numSubjects": "9"}]}, {"type": "Treatment Non-compliance", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "3"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Participants who received at least 1 dose of LY2189265 or Metformin.", "groups": [{"id": "BG000", "title": "1.5 mg LY2189265", "description": "LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}, {"id": "BG001", "title": "0.75 mg LY2189265", "description": "LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}, {"id": "BG002", "title": "Metformin", "description": "Metformin: 2000 milligrams per day (mg/day) or at least 1500 mg/day, orally, for 52 weeks\n\nPlacebo: subcutaneously (SC), once weekly for 52 weeks"}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "269"}, {"groupId": "BG001", "value": "270"}, {"groupId": "BG002", "value": "268"}, {"groupId": "BG003", "value": "807"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "55.51", "spread": "10.38"}, {"groupId": "BG001", "value": "55.90", "spread": "10.68"}, {"groupId": "BG002", "value": "55.26", "spread": "10.10"}, {"groupId": "BG003", "value": "55.56", "spread": "10.38"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "155"}, {"groupId": "BG001", "value": "152"}, {"groupId": "BG002", "value": "147"}, {"groupId": "BG003", "value": "454"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "114"}, {"groupId": "BG001", "value": "118"}, {"groupId": "BG002", "value": "121"}, {"groupId": "BG003", "value": "353"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "90"}, {"groupId": "BG001", "value": "87"}, {"groupId": "BG002", "value": "95"}, {"groupId": "BG003", "value": "272"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "179"}, {"groupId": "BG001", "value": "183"}, {"groupId": "BG002", "value": "173"}, {"groupId": "BG003", "value": "535"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "29"}, {"groupId": "BG001", "value": "28"}, {"groupId": "BG002", "value": "28"}, {"groupId": "BG003", "value": "85"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "21"}, {"groupId": "BG001", "value": "20"}, {"groupId": "BG002", "value": "20"}, {"groupId": "BG003", "value": "61"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "1"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "17"}, {"groupId": "BG001", "value": "22"}, {"groupId": "BG002", "value": "14"}, {"groupId": "BG003", "value": "53"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "201"}, {"groupId": "BG001", "value": "198"}, {"groupId": "BG002", "value": "201"}, {"groupId": "BG003", "value": "600"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "4"}, {"groupId": "BG003", "value": "7"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "77"}, {"groupId": "BG001", "value": "80"}, {"groupId": "BG002", "value": "74"}, {"groupId": "BG003", "value": "231"}]}]}, {"title": "Slovakia", "categories": [{"measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "9"}, {"groupId": "BG003", "value": "26"}]}]}, {"title": "Finland", "categories": [{"measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "4"}, {"groupId": "BG003", "value": "12"}]}]}, {"title": "Spain", "categories": [{"measurements": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "12"}, {"groupId": "BG003", "value": "35"}]}]}, {"title": "United Kingdom", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "2"}]}]}, {"title": "India", "categories": [{"measurements": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "9"}, {"groupId": "BG003", "value": "29"}]}]}, {"title": "France", "categories": [{"measurements": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "12"}, {"groupId": "BG002", "value": "13"}, {"groupId": "BG003", "value": "37"}]}]}, {"title": "Czech Republic", "categories": [{"measurements": [{"groupId": "BG000", "value": "10"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "8"}, {"groupId": "BG003", "value": "27"}]}]}, {"title": "Mexico", "categories": [{"measurements": [{"groupId": "BG000", "value": "24"}, {"groupId": "BG001", "value": "25"}, {"groupId": "BG002", "value": "23"}, {"groupId": "BG003", "value": "72"}]}]}, {"title": "Canada", "categories": [{"measurements": [{"groupId": "BG000", "value": "10"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "11"}, {"groupId": "BG003", "value": "30"}]}]}, {"title": "Puerto Rico", "categories": [{"measurements": [{"groupId": "BG000", "value": "14"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "15"}, {"groupId": "BG003", "value": "39"}]}]}, {"title": "Argentina", "categories": [{"measurements": [{"groupId": "BG000", "value": "27"}, {"groupId": "BG001", "value": "27"}, {"groupId": "BG002", "value": "26"}, {"groupId": "BG003", "value": "80"}]}]}, {"title": "Poland", "categories": [{"measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "18"}]}]}, {"title": "Brazil", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "7"}]}]}, {"title": "Croatia", "categories": [{"measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "4"}, {"groupId": "BG003", "value": "11"}]}]}, {"title": "Romania", "categories": [{"measurements": [{"groupId": "BG000", "value": "14"}, {"groupId": "BG001", "value": "13"}, {"groupId": "BG002", "value": "13"}, {"groupId": "BG003", "value": "40"}]}]}, {"title": "South Africa", "categories": [{"measurements": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "12"}, {"groupId": "BG003", "value": "35"}]}]}, {"title": "Germany", "categories": [{"measurements": [{"groupId": "BG000", "value": "22"}, {"groupId": "BG001", "value": "21"}, {"groupId": "BG002", "value": "21"}, {"groupId": "BG003", "value": "64"}]}]}, {"title": "Korea, Republic of", "categories": [{"measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "12"}]}]}]}, {"title": "Body Weight", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kilograms (kg)", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "92.67", "spread": "18.79"}, {"groupId": "BG001", "value": "91.79", "spread": "18.67"}, {"groupId": "BG002", "value": "92.40", "spread": "19.23"}, {"groupId": "BG003", "value": "92.28", "spread": "18.87"}]}]}]}, {"title": "Body Mass Index (BMI)", "description": "Body mass index is an estimate of body fat based on body weight divided by height squared.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kilograms per square meter (kg/m^2)", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "33.66", "spread": "5.65"}, {"groupId": "BG001", "value": "33.08", "spread": "5.84"}, {"groupId": "BG002", "value": "33.05", "spread": "5.06"}, {"groupId": "BG003", "value": "33.26", "spread": "5.53"}]}]}]}, {"title": "Duration of Diabetes", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "2.65", "spread": "1.50"}, {"groupId": "BG001", "value": "2.60", "spread": "2.17"}, {"groupId": "BG002", "value": "2.63", "spread": "1.77"}, {"groupId": "BG003", "value": "2.63", "spread": "1.83"}]}]}]}, {"title": "Glycosylated Hemoglobin (HbA1c)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "percentage of glycosylated hemoglobin", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "7.63", "spread": "0.92"}, {"groupId": "BG001", "value": "7.58", "spread": "0.87"}, {"groupId": "BG002", "value": "7.60", "spread": "0.82"}, {"groupId": "BG003", "value": "7.60", "spread": "0.87"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline to 26-week Endpoint in Glycosylated Hemoglobin (HbA1c)", "description": "Least Squares (LS) means were calculated using analysis of covariance (ANCOVA) with country, treatment, and prior medication group (previous oral antihyperglycemic medication \\[OAM\\] versus no previous OAM) as fixed effects and baseline HbA1c as a covariate.", "populationDescription": "Participants who received at least one dose of LY2189265 or Metformin with evaluable HbA1c data. Only pre-rescue measurements were used. Last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage of glycosylated hemoglobin", "timeFrame": "Baseline, 26 weeks", "groups": [{"id": "OG000", "title": "1.5 mg LY2189265", "description": "LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}, {"id": "OG001", "title": "0.75 mg LY2189265", "description": "LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}, {"id": "OG002", "title": "Metformin", "description": "Metformin: 2000 milligrams per day (mg/day) or at least 1500 mg/day, orally, for 52 weeks\n\nPlacebo: subcutaneously (SC), once weekly for 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "265"}, {"groupId": "OG001", "value": "265"}, {"groupId": "OG002", "value": "265"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.78", "spread": "0.06"}, {"groupId": "OG001", "value": "-0.71", "spread": "0.06"}, {"groupId": "OG002", "value": "-0.56", "spread": "0.06"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "groupDescription": "The study was designed with 90% power to detect non-inferiority of 1.5 mg LY2189265 vs Metformin on HbA1c change from baseline at the 26-week primary endpoint with a margin of 0.4%, a standard deviation of 1.3%, and a 2-sided alpha of 0.05 assuming no true difference between treatments. This corresponds to 223 participants per arm, with an assumed drop-out rate of 11%.", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "A non-inferiority margin of 0.4% was used.", "pValue": "<0.001", "pValueComment": "The p-value is adjusted for multiplicity using a tree-gatekeeping strategy. To determine significance, the p-value is compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.", "statisticalMethod": "ANCOVA", "paramType": "LS Mean Difference", "paramValue": "-0.22", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.36", "ciUpperLimit": "-0.08"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "A non-inferiority margin of 0.4% was used.", "pValue": "<0.001", "pValueComment": "The p-value is adjusted for multiplicity using a tree-gatekeeping strategy. To determine significance, the p-value is compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.", "statisticalMethod": "ANCOVA", "paramType": "LS Mean Difference", "paramValue": "-0.15", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.29", "ciUpperLimit": "-0.01"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Superiority analysis.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.002", "pValueComment": "Tree gatekeeping strategy to control the family-wise Type I error rate was applied.", "statisticalMethod": "ANCOVA", "paramType": "LS Mean Difference", "paramValue": "-0.22", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.36", "ciUpperLimit": "-0.08"}, {"groupIds": ["OG001", "OG002"], "groupDescription": "Superiority analysis.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.020", "pValueComment": "Tree gatekeeping strategy to control the family-wise Type I error rate was applied.", "statisticalMethod": "ANCOVA", "paramType": "LS Mean Difference", "paramValue": "-0.15", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.29", "ciUpperLimit": "-0.01"}]}, {"type": "SECONDARY", "title": "Change From Baseline to 52-week Endpoint in Glycosylated Hemoglobin (HbA1c)", "description": "Least Squares (LS) means were calculated using analysis of covariance (ANCOVA) with country, treatment, and prior medication group (previous oral antihyperglycemic medication \\[OAM\\] versus no previous OAM) as fixed effects and baseline HbA1c as a covariate.", "populationDescription": "Participants who received at least one dose of LY2189265 or Metformin with evaluable HbA1c data. Only pre-rescue measurements were used. Last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage of glycosylated hemoglobin", "timeFrame": "Baseline, 52 weeks", "groups": [{"id": "OG000", "title": "1.5 mg LY2189265", "description": "LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}, {"id": "OG001", "title": "0.75 mg LY2189265", "description": "LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}, {"id": "OG002", "title": "Metformin", "description": "Metformin: 2000 milligrams per day (mg/day) or at least 1500 mg/day, orally, for 52 weeks\n\nPlacebo: subcutaneously (SC), once weekly for 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "265"}, {"groupId": "OG001", "value": "265"}, {"groupId": "OG002", "value": "265"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.70", "spread": "0.07"}, {"groupId": "OG001", "value": "-0.55", "spread": "0.07"}, {"groupId": "OG002", "value": "-0.51", "spread": "0.07"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "A non-inferiority margin of 0.4% was used.", "pValue": "<0.001", "pValueComment": "The p-value is adjusted for multiplicity using a tree-gatekeeping strategy. To determine significance, the p-value is compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.", "statisticalMethod": "ANCOVA", "paramType": "LS Mean Difference", "paramValue": "-0.19", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.35", "ciUpperLimit": "-0.02"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "A non-inferiority margin of 0.4% was used.", "pValue": "<0.001", "pValueComment": "The p-value is adjusted for multiplicity using a tree-gatekeeping strategy. To determine significance, the p-value is compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.", "statisticalMethod": "ANCOVA", "paramType": "LS Mean Difference", "paramValue": "-0.04", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.20", "ciUpperLimit": "0.12"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Superiority analysis.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.024", "pValueComment": "Tree gatekeeping strategy to control the family-wise Type I error rate was applied.", "statisticalMethod": "ANCOVA", "paramType": "LS Mean Difference", "paramValue": "-0.19", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.35", "ciUpperLimit": "-0.02"}, {"groupIds": ["OG001", "OG002"], "groupDescription": "Superiority analysis.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.299", "pValueComment": "Tree gatekeeping strategy to control the family-wise Type I error rate was applied.", "statisticalMethod": "ANCOVA", "paramType": "LS Mean Difference", "paramValue": "-0.04", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.20", "ciUpperLimit": "0.12"}]}, {"type": "SECONDARY", "title": "Percentage of Participants Achieving a Glycosylated Hemoglobin (HbA1c) of Less Than 7% and Less Than or Equal to 6.5% at 26 and 52 Weeks", "description": "The percentage of participants achieving HbA1c level less than 7.0% and less than or equal to 6.5% was analyzed with a logistic regression model with baseline, prior medication group, and treatment as factors included in the model.", "populationDescription": "Participants who received at least one dose of LY2189265 or Metformin with evaluable HbA1c data. Only pre-rescue measurements were used. Last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "26 weeks and 52 weeks", "groups": [{"id": "OG000", "title": "1.5 mg LY2189265", "description": "LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}, {"id": "OG001", "title": "0.75 mg LY2189265", "description": "LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}, {"id": "OG002", "title": "Metformin", "description": "Metformin: 2000 milligrams per day (mg/day) or at least 1500 mg/day, orally, for 52 weeks\n\nPlacebo: subcutaneously (SC), once weekly for 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "265"}, {"groupId": "OG001", "value": "265"}, {"groupId": "OG002", "value": "265"}]}], "classes": [{"title": "HbA1c less than 7%, 26 weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "61.5"}, {"groupId": "OG001", "value": "62.6"}, {"groupId": "OG002", "value": "53.6"}]}]}, {"title": "HbA1c less than or equal to 6.5%, 26 weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "46.0"}, {"groupId": "OG001", "value": "40.0"}, {"groupId": "OG002", "value": "29.8"}]}]}, {"title": "HbA1c less than 7%, 52 weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "60.0"}, {"groupId": "OG001", "value": "53.2"}, {"groupId": "OG002", "value": "48.3"}]}]}, {"title": "HbA1c less than or equal to 6.5%, 52 weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "42.3"}, {"groupId": "OG001", "value": "34.7"}, {"groupId": "OG002", "value": "28.3"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.023", "pValueComment": "Treatment comparison for HbA1c less than 7.0% at 26 weeks.", "statisticalMethod": "Regression, Logistic"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.021", "pValueComment": "Treatment comparison for HbA1c less than 7.0% at 26 weeks.", "statisticalMethod": "Regression, Logistic"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Treatment comparison for HbA1c less than or equal to 6.5% at 26 weeks.", "statisticalMethod": "Regression, Logistic"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.011", "pValueComment": "Treatment comparison for HbA1c less than or equal to 6.5% at 26 weeks.", "statisticalMethod": "Regression, Logistic"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.001", "pValueComment": "Treatment comparison for HbA1c less than 7% at 52 weeks.", "statisticalMethod": "Regression, Logistic"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.269", "pValueComment": "Treatment comparison for HbA1c less than 7% at 52 weeks.", "statisticalMethod": "Regression, Logistic"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Treatment comparison for HbA1c less than or equal to 6.5% at 52 weeks.", "statisticalMethod": "Regression, Logistic"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.134", "pValueComment": "Treatment comparison for HbA1c less than or equal to 6.5% at 52 weeks.", "statisticalMethod": "Regression, Logistic"}]}, {"type": "SECONDARY", "title": "Change From Baseline to 26 and 52 Weeks in Fasting Blood Glucose", "description": "Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, prior medication group, visit, and treatment-by-visit interaction as fixed effects, baseline fasting blood glucose as a covariate, and participant as a random effect.", "populationDescription": "Participants who received at least one dose of LY2189265 or Metformin with evaluable fasting blood glucose data. Only pre-rescue measurements were used.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "millimoles per liter (mmol/L)", "timeFrame": "Baseline, 26 weeks, and 52 weeks", "groups": [{"id": "OG000", "title": "1.5 mg LY2189265", "description": "LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}, {"id": "OG001", "title": "0.75 mg LY2189265", "description": "LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}, {"id": "OG002", "title": "Metformin", "description": "Metformin: 2000 milligrams per day (mg/day) or at least 1500 mg/day, orally, for 52 weeks\n\nPlacebo: subcutaneously (SC), once weekly for 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "267"}, {"groupId": "OG001", "value": "265"}, {"groupId": "OG002", "value": "264"}]}], "classes": [{"title": "26 weeks (n=244, 247, 245)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.61", "spread": "0.13"}, {"groupId": "OG001", "value": "-1.46", "spread": "0.13"}, {"groupId": "OG002", "value": "-1.34", "spread": "0.13"}]}]}, {"title": "52 weeks (n=207, 210, 194)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.56", "spread": "0.14"}, {"groupId": "OG001", "value": "-1.00", "spread": "0.14"}, {"groupId": "OG002", "value": "-1.15", "spread": "0.14"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.079", "pValueComment": "Treatment comparison at 26 weeks.", "statisticalMethod": "Mixed Models Analysis"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.451", "pValueComment": "Treatment comparison at 26 weeks.", "statisticalMethod": "Mixed Models Analysis"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.025", "pValueComment": "Treatment comparison at 52 weeks.", "statisticalMethod": "Mixed Models Analysis"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.402", "pValueComment": "Treatment comparison at 52 weeks.", "statisticalMethod": "Mixed Models Analysis"}]}, {"type": "SECONDARY", "title": "Change From Baseline to 26 and 52 Weeks in Daily Mean Blood Glucose Values From the 8-point Self-monitored Blood Glucose (SMBG) Profiles", "description": "The SMBG data were collected at the following 8 time points: pre-morning meal; 2 hours post-morning meal; pre-midday meal; 2 hours post-midday meal; pre-evening; 2 hours post-evening meal; bedtime; and 3AM or 5 hours after bedtime. Least Squares (LS) means of the mean of the 8 time points (daily mean) were calculated using analysis of covariance (ANCOVA) with country, treatment, and prior medication group as fixed effects and baseline daily mean as a covariate.", "populationDescription": "Participants who received at least one dose of LY2189265 or Metformin with evaluable SMBG data. Only pre-rescue measurements were used. Last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "millimoles per liter (mmol/L)", "timeFrame": "Baseline, 26 weeks, and 52 weeks", "groups": [{"id": "OG000", "title": "1.5 mg LY2189265", "description": "LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}, {"id": "OG001", "title": "0.75 mg LY2189265", "description": "LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}, {"id": "OG002", "title": "Metformin", "description": "Metformin: 2000 milligrams per day (mg/day) or at least 1500 mg/day, orally, for 52 weeks\n\nPlacebo: subcutaneously (SC), once weekly for 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "211"}, {"groupId": "OG001", "value": "207"}, {"groupId": "OG002", "value": "218"}]}], "classes": [{"title": "26 weeks (n=195, 200, 211)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.98", "spread": "0.15"}, {"groupId": "OG001", "value": "-1.75", "spread": "0.14"}, {"groupId": "OG002", "value": "-1.68", "spread": "0.14"}]}]}, {"title": "52 weeks (n=197, 200, 212)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.99", "spread": "0.16"}, {"groupId": "OG001", "value": "-1.71", "spread": "0.16"}, {"groupId": "OG002", "value": "-1.58", "spread": "0.15"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.061", "pValueComment": "Treatment comparison at 26 weeks.", "statisticalMethod": "ANCOVA"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.647", "pValueComment": "Treatment comparison at 26 weeks.", "statisticalMethod": "ANCOVA"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.022", "pValueComment": "Treatment comparison at 52 weeks.", "statisticalMethod": "ANCOVA"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.469", "pValueComment": "Treatment comparison at 52 weeks.", "statisticalMethod": "ANCOVA"}]}, {"type": "SECONDARY", "title": "Change From Baseline to 26 and 52 Weeks in Body Weight", "description": "Least Squares (LS) means were calculated using analysis of covariance (ANCOVA) with country, treatment, and prior medication group as fixed effects and baseline body weight as a covariate.", "populationDescription": "Participants who received at least one dose of LY2189265 or Metformin with evaluable body weight data. Only pre-rescue measurements were used. Last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "kilograms (kg)", "timeFrame": "Baseline, 26 weeks, and 52 weeks", "groups": [{"id": "OG000", "title": "1.5 mg LY2189265", "description": "LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}, {"id": "OG001", "title": "0.75 mg LY2189265", "description": "LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}, {"id": "OG002", "title": "Metformin", "description": "Metformin: 2000 milligrams per day (mg/day) or at least 1500 mg/day, orally, for 52 weeks\n\nPlacebo: subcutaneously (SC), once weekly for 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "269"}, {"groupId": "OG001", "value": "270"}, {"groupId": "OG002", "value": "268"}]}], "classes": [{"title": "26 weeks (n=267, 269, 267)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.29", "spread": "0.24"}, {"groupId": "OG001", "value": "-1.36", "spread": "0.24"}, {"groupId": "OG002", "value": "-2.22", "spread": "0.24"}]}]}, {"title": "52 weeks (n=267, 269, 267)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.93", "spread": "0.29"}, {"groupId": "OG001", "value": "-1.09", "spread": "0.29"}, {"groupId": "OG002", "value": "-2.20", "spread": "0.29"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.811", "pValueComment": "Treatment comparison at 26 weeks.", "statisticalMethod": "ANCOVA"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.003", "pValueComment": "Treatment comparison at 26 weeks.", "statisticalMethod": "ANCOVA"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.440", "pValueComment": "Treatment comparison at 52 weeks.", "statisticalMethod": "ANCOVA"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.001", "pValueComment": "Treatment comparison at 52 weeks.", "statisticalMethod": "ANCOVA"}]}, {"type": "SECONDARY", "title": "Change From Baseline to 26 and 52 Weeks in Body Mass Index (BMI)", "description": "Body mass index is an estimate of body fat based on body weight divided by height squared. Least Squares (LS) means were calculated using analysis of covariance (ANCOVA) with country, treatment, and prior medication group as fixed effects and baseline BMI as a covariate.", "populationDescription": "Participants who received at least one dose of LY2189265 or Metformin with evaluable BMI data. Only pre-rescue measurements were used. Last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "kilograms per meter squared (kg/m^2)", "timeFrame": "Baseline, 26 weeks, and 52 weeks", "groups": [{"id": "OG000", "title": "1.5 mg LY2189265", "description": "LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}, {"id": "OG001", "title": "0.75 mg LY2189265", "description": "LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}, {"id": "OG002", "title": "Metformin", "description": "Metformin: 2000 milligrams per day (mg/day) or at least 1500 mg/day, orally, for 52 weeks\n\nPlacebo: subcutaneously (SC), once weekly for 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "267"}, {"groupId": "OG001", "value": "269"}, {"groupId": "OG002", "value": "267"}]}], "classes": [{"title": "26 weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.86", "spread": "0.09"}, {"groupId": "OG001", "value": "-0.51", "spread": "0.09"}, {"groupId": "OG002", "value": "-0.82", "spread": "0.09"}]}]}, {"title": "52 weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.73", "spread": "0.11"}, {"groupId": "OG001", "value": "-0.42", "spread": "0.10"}, {"groupId": "OG002", "value": "-0.83", "spread": "0.11"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.750", "pValueComment": "Treatment comparison at 26 weeks.", "statisticalMethod": "ANCOVA"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.003", "pValueComment": "Treatment comparison at 26 weeks.", "statisticalMethod": "ANCOVA"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.412", "pValueComment": "Treatment comparison at 52 weeks.", "statisticalMethod": "ANCOVA"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.001", "pValueComment": "Treatment comparison at 52 weeks.", "statisticalMethod": "ANCOVA"}]}, {"type": "SECONDARY", "title": "Change From Baseline to 26 and 52 Weeks in Homeostasis Model Assessment of Beta-cell Function", "description": "The homeostatic model assessment (HOMA) quantifies insulin resistance and beta-cell function. HOMA2-B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady-state beta cell function (%B) as a percentage of a normal reference population (normal young adults). HOMA2-S is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin sensitivity (%S) as percentages of a normal reference population (normal young adults). The normal reference populations were set at 100%. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, prior medication group, visit, and treatment-by-visit interaction as fixed effects, baseline HOMA2 as a covariate, and participant as a random effect.", "populationDescription": "Participants who received at least one dose of LY2189265 or Metformin with evaluable HOMA2-%B or HOMA2-%S data. Only pre-rescue measurements were used.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage of HOMA2", "timeFrame": "Baseline, 26 weeks, and 52 weeks", "groups": [{"id": "OG000", "title": "1.5 mg LY2189265", "description": "LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}, {"id": "OG001", "title": "0.75 mg LY2189265", "description": "LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}, {"id": "OG002", "title": "Metformin", "description": "Metformin: 2000 milligrams per day (mg/day) or at least 1500 mg/day, orally, for 52 weeks\n\nPlacebo: subcutaneously (SC), once weekly for 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "245"}, {"groupId": "OG001", "value": "242"}, {"groupId": "OG002", "value": "242"}]}], "classes": [{"title": "HOMA2-%B, 26 weeks (n=207, 207, 215)", "categories": [{"measurements": [{"groupId": "OG000", "value": "36.55", "spread": "3.42"}, {"groupId": "OG001", "value": "28.96", "spread": "3.44"}, {"groupId": "OG002", "value": "14.11", "spread": "3.37"}]}]}, {"title": "HOMA2-%B, 52 weeks (n=179, 185, 170)", "categories": [{"measurements": [{"groupId": "OG000", "value": "29.97", "spread": "3.46"}, {"groupId": "OG001", "value": "22.5", "spread": "3.46"}, {"groupId": "OG002", "value": "9.77", "spread": "3.51"}]}]}, {"title": "HOMA2-%S, 26 weeks (n=207, 207, 215)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.95", "spread": "2.29"}, {"groupId": "OG001", "value": "2.71", "spread": "2.29"}, {"groupId": "OG002", "value": "9.99", "spread": "2.25"}]}]}, {"title": "HOMA2-%S, 52 weeks (n=179, 185, 170)", "categories": [{"measurements": [{"groupId": "OG000", "value": "5.29", "spread": "2.43"}, {"groupId": "OG001", "value": "1.84", "spread": "2.43"}, {"groupId": "OG002", "value": "10.83", "spread": "2.48"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Treatment comparison of HOMA2-%B at 26 weeks.", "statisticalMethod": "Mixed Models Analysis"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Treatment comparison of HOMA2-%B at 26 weeks.", "statisticalMethod": "Mixed Models Analysis"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Treatment comparison of HOMA2-%B at 52 weeks.", "statisticalMethod": "Mixed Models Analysis"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.003", "pValueComment": "Treatment comparison of HOMA2-%B at 52 weeks.", "statisticalMethod": "Mixed Models Analysis"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.001", "pValueComment": "Treatment comparison of HOMA2-%S at 26 weeks.", "statisticalMethod": "Mixed Models Analysis"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.010", "pValueComment": "Treatment comparison of HOMA2-%S at 26 weeks.", "statisticalMethod": "Mixed Models Analysis"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.077", "pValueComment": "Treatment comparison of HOMA2-%S at 52 weeks.", "statisticalMethod": "Mixed Models Analysis"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.004", "pValueComment": "Treatment comparison of HOMA2-%S at 52 weeks.", "statisticalMethod": "Mixed Models Analysis"}]}, {"type": "SECONDARY", "title": "Change From Baseline to 26 and 52 Weeks in the Impact of Weight on Activities of Daily Living (IW-ADL) Score", "description": "The Impact of Weight on Activities of Daily Living (renamed the Ability to Perform Physical Activities of Daily Living \\[APPADL\\]) questionnaire contains 7 items that assess how difficult it is for participants to engage in certain activities considered to be integral to normal daily life, such as walking, standing and climbing stairs. Items are scored on a 5-point numeric rating scale where 5 = \"not at all difficult\" and 1 = \"unable to do\". The individual scores from all 7 items are summed and a single total score is calculated and may range between 7 and 35. A higher score indicates better ability to perform activities of daily living. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusted by treatment, country, prior medication group, gender, and baseline score.", "populationDescription": "Participants who received at least one dose of LY2189265 or Metformin with evaluable APPADL data. Only pre-rescue measurements were used. Last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline, 26 weeks, and 52 weeks", "groups": [{"id": "OG000", "title": "1.5 mg LY2189265", "description": "LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}, {"id": "OG001", "title": "0.75 mg LY2189265", "description": "LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}, {"id": "OG002", "title": "Metformin", "description": "Metformin: 2000 milligrams per day (mg/day) or at least 1500 mg/day, orally, for 52 weeks\n\nPlacebo: subcutaneously (SC), once weekly for 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "266"}, {"groupId": "OG001", "value": "268"}, {"groupId": "OG002", "value": "266"}]}], "classes": [{"title": "26 weeks (n=247, 251, 247)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.09", "spread": "0.33"}, {"groupId": "OG001", "value": "0.19", "spread": "0.32"}, {"groupId": "OG002", "value": "0.02", "spread": "0.32"}]}]}, {"title": "52 weeks (n=247, 252, 248)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.39", "spread": "0.33"}, {"groupId": "OG001", "value": "-0.05", "spread": "0.33"}, {"groupId": "OG002", "value": "0.28", "spread": "0.33"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to 26 and 52 Weeks in the Impact of Weight on Self-Perception (IW-SP) Score", "description": "The Impact of Weight on Self-Perception (IW-SP) questionnaire contains 3 items that assess how often the participants' body weight affects how happy they are with their appearance and how often they feel self-conscious when out in public. Items are scored on a 5-point numeric rating scale where 5 = never and 1 = always. A single total score is calculated by summing the scores for all 3 items. Total score ranges between 3 and 15, where a higher score is indicative of better self-perception. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusted by treatment, country, prior medication group, gender, and baseline score.", "populationDescription": "Participants who received at least one dose of LY2189265 or Metformin with evaluable IW-SP data. Only pre-rescue measurements were used. Last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline, 26 weeks, and 52 weeks", "groups": [{"id": "OG000", "title": "1.5 mg LY2189265", "description": "LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}, {"id": "OG001", "title": "0.75 mg LY2189265", "description": "LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}, {"id": "OG002", "title": "Metformin", "description": "Metformin: 2000 milligrams per day (mg/day) or at least 1500 mg/day, orally, for 52 weeks\n\nPlacebo: subcutaneously (SC), once weekly for 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "268"}, {"groupId": "OG001", "value": "270"}, {"groupId": "OG002", "value": "268"}]}], "classes": [{"title": "26 weeks (n=248, 254, 249)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.72", "spread": "0.19"}, {"groupId": "OG001", "value": "0.63", "spread": "0.18"}, {"groupId": "OG002", "value": "0.79", "spread": "0.18"}]}]}, {"title": "52 weeks (n=249, 255, 250)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.45", "spread": "0.19"}, {"groupId": "OG001", "value": "0.61", "spread": "0.19"}, {"groupId": "OG002", "value": "0.75", "spread": "0.19"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to 26 and 52 Weeks in the Diabetes Treatment Satisfaction Questionnaire (DTSQ) Score, Status Version", "description": "The Diabetes Treatment Satisfaction Questionnaire status version (DTSQs) is used to assess participant treatment satisfaction at each study visit. The questionnaire consists of 8 items, 6 of which (1 and 4 through 8) assess treatment satisfaction. Each item is rated on a 7-point Likert scale. Scores from the 6 treatment satisfaction items are summed to a Total Treatment Satisfaction Score, which ranges from 0 (very dissatisfied) to 36 (very satisfied). Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusted by treatment, country, prior medication group, gender, and baseline score.", "populationDescription": "Participants who received at least one dose of LY2189265 or Metformin with evaluable DTSQs data. Only pre-rescue measurements were used. Last observation carried forward (LOCF) used to impute missing postbaseline values. If there were no data after randomization, endpoint was considered missing.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline, 26 weeks, and 52 weeks", "groups": [{"id": "OG000", "title": "1.5 mg LY2189265", "description": "LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}, {"id": "OG001", "title": "0.75 mg LY2189265", "description": "LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}, {"id": "OG002", "title": "Metformin", "description": "Metformin: 2000 milligrams per day (mg/day) or at least 1500 mg/day, orally, for 52 weeks\n\nPlacebo: subcutaneously (SC), once weekly for 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "266"}, {"groupId": "OG001", "value": "267"}, {"groupId": "OG002", "value": "267"}]}], "classes": [{"title": "26 weeks (n=244, 249, 241)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.93", "spread": "0.39"}, {"groupId": "OG001", "value": "1.81", "spread": "0.38"}, {"groupId": "OG002", "value": "2.04", "spread": "0.39"}]}]}, {"title": "52 weeks (n=245, 251, 244)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.82", "spread": "0.44"}, {"groupId": "OG001", "value": "1.29", "spread": "0.43"}, {"groupId": "OG002", "value": "1.94", "spread": "0.44"}]}]}]}, {"type": "SECONDARY", "title": "Diabetes Treatment Satisfaction Questionnaire (DTSQ) Score, Change Version", "description": "The Diabetes Treatment Satisfaction Questionnaire change (DTSQc) score is used to assess relative change in participant satisfaction from baseline. The questionnaire consists of 8 items, 6 of which (1 and 4 through 8) assess treatment satisfaction. Each item is rated on a 7-point Likert scale. The scores from the 6 treatment satisfaction items are summed to a Total Treatment Satisfaction Score, which ranges from -18 (much less satisfied) to +18 (much more satisfied). Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusted by treatment, country, prior medication group, gender, and baseline score.", "populationDescription": "Participants who received at least one dose of LY2189265 or Metformin with evaluable DTSQc data. Only pre-rescue measurements were used. Last observation carried forward (LOCF) used to impute missing postbaseline values. If there were no data after randomization, endpoint was considered missing.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "52 weeks", "groups": [{"id": "OG000", "title": "1.5 mg LY2189265", "description": "LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}, {"id": "OG001", "title": "0.75 mg LY2189265", "description": "LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}, {"id": "OG002", "title": "Metformin", "description": "Metformin: 2000 milligrams per day (mg/day) or at least 1500 mg/day, orally, for 52 weeks\n\nPlacebo: subcutaneously (SC), once weekly for 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "230"}, {"groupId": "OG001", "value": "235"}, {"groupId": "OG002", "value": "230"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "12.92", "spread": "0.52"}, {"groupId": "OG001", "value": "12.73", "spread": "0.50"}, {"groupId": "OG002", "value": "12.58", "spread": "0.51"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to 26 and 52 Weeks in the Diabetes Symptoms Checklist Participant-reported Outcome (DSC-r) Score", "description": "The Diabetes Symptoms Checklist-revised (DSC-r) was designed to assess the presence and perceived burden of diabetes-related symptoms. Respondents were to consider troublesomeness of 34 symptoms on a 5-point scale ranging from 5=\"extremely\" to 1=\"not at all.\" For symptoms/side-effects not experienced, the item was scored as 0. Symptoms were grouped into the following subscales: psychology-fatigue, psychology-cognitive, neurology-pain, neurology-sensory, cardiology, ophthalmology, hypoglycemia, and hyperglycemia. Subscale scores were calculated as the sum of the given subscale divided by the total number of items in the scale. Total score was computed from the sum of the 8 subscales and ranged from 0 to 40. Higher scores indicate greater symptom burden. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusted by treatment, country, prior medication group, gender, and baseline score.", "populationDescription": "Participants who received at least one dose of LY2189265 or Metformin with evaluable DSC-r data. Only pre-rescue measurements were used. Last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline, 26 weeks, and 52 weeks", "groups": [{"id": "OG000", "title": "1.5 mg LY2189265", "description": "LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}, {"id": "OG001", "title": "0.75 mg LY2189265", "description": "LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}, {"id": "OG002", "title": "Metformin", "description": "Metformin: 2000 milligrams per day (mg/day) or at least 1500 mg/day, orally, for 52 weeks\n\nPlacebo: subcutaneously (SC), once weekly for 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "267"}, {"groupId": "OG001", "value": "270"}, {"groupId": "OG002", "value": "267"}]}], "classes": [{"title": "26 weeks (n=245, 253, 248)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.24", "spread": "0.36"}, {"groupId": "OG001", "value": "-0.16", "spread": "0.35"}, {"groupId": "OG002", "value": "0.41", "spread": "0.35"}]}]}, {"title": "52 weeks (n=247, 255, 249)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.49", "spread": "0.39"}, {"groupId": "OG001", "value": "0.42", "spread": "0.39"}, {"groupId": "OG002", "value": "0.59", "spread": "0.39"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Treatment Emergent Adverse Events at 26 and 52 Weeks", "description": "A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with one or more TEAE is summarized cumulatively at 26 and 52 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.", "populationDescription": "Participants who received at least one dose of LY2189265 or Metformin.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "26 weeks and 52 weeks", "groups": [{"id": "OG000", "title": "1.5 mg LY2189265", "description": "LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}, {"id": "OG001", "title": "0.75 mg LY2189265", "description": "LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}, {"id": "OG002", "title": "Metformin", "description": "Metformin: 2000 milligrams per day (mg/day) or at least 1500 mg/day, orally, for 52 weeks\n\nPlacebo: subcutaneously (SC), once weekly for 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "269"}, {"groupId": "OG001", "value": "270"}, {"groupId": "OG002", "value": "268"}]}], "classes": [{"title": "26 weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "163"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "151"}]}]}, {"title": "52 weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "179"}, {"groupId": "OG001", "value": "177"}, {"groupId": "OG002", "value": "170"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to 26 and 52 Weeks in Electrocardiogram Parameters, Fridericia Corrected QT (QTcF) Interval and PR Interval", "description": "The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR\\^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. PR is the interval between the P wave and the QRS complex. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, prior medication group, visit, and treatment-by-visit interaction as fixed effects, baseline interval as a covariate, and participant as a random effect.", "populationDescription": "Participants who received at least one dose of LY2189265 or Metformin with evaluable ECG QTcF interval or PR interval data.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "milliseconds (msec)", "timeFrame": "Baseline, 26 weeks, and 52 weeks", "groups": [{"id": "OG000", "title": "1.5 mg LY2189265", "description": "LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}, {"id": "OG001", "title": "0.75 mg LY2189265", "description": "LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}, {"id": "OG002", "title": "Metformin", "description": "Metformin: 2000 milligrams per day (mg/day) or at least 1500 mg/day, orally, for 52 weeks\n\nPlacebo: subcutaneously (SC), once weekly for 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "269"}, {"groupId": "OG001", "value": "270"}, {"groupId": "OG002", "value": "268"}]}], "classes": [{"title": "QTcF interval, 26 weeks (n=230, 237, 221)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.60", "spread": "1.17"}, {"groupId": "OG001", "value": "1.38", "spread": "1.16"}, {"groupId": "OG002", "value": "-0.91", "spread": "1.18"}]}]}, {"title": "QTcF interval, 52 weeks (n=212, 212, 205)", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.76", "spread": "1.20"}, {"groupId": "OG001", "value": "0.73", "spread": "1.19"}, {"groupId": "OG002", "value": "-0.53", "spread": "1.21"}]}]}, {"title": "PR interval, 26 weeks (n=226, 235, 218)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.04", "spread": "1.12"}, {"groupId": "OG001", "value": "-0.01", "spread": "1.10"}, {"groupId": "OG002", "value": "-2.04", "spread": "1.13"}]}]}, {"title": "PR interval, 52 weeks (n=209, 210, 201)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.15", "spread": "1.18"}, {"groupId": "OG001", "value": "1.53", "spread": "1.17"}, {"groupId": "OG002", "value": "-2.88", "spread": "1.19"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to 26 and 52 Weeks in Electrocardiogram Parameters, Heart Rate", "description": "Electrocardiogram (ECG) heart rate was measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, prior medication group, visit, and treatment-by-visit interaction as fixed effects and baseline interval as a covariate.", "populationDescription": "Participants who received at least one dose of LY2189265 or Metformin with evaluable ECG heart rate data.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "beats per minute (bpm)", "timeFrame": "Baseline, 26 weeks, and 52 weeks", "groups": [{"id": "OG000", "title": "1.5 mg LY2189265", "description": "LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}, {"id": "OG001", "title": "0.75 mg LY2189265", "description": "LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}, {"id": "OG002", "title": "Metformin", "description": "Metformin: 2000 milligrams per day (mg/day) or at least 1500 mg/day, orally, for 52 weeks\n\nPlacebo: subcutaneously (SC), once weekly for 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "267"}, {"groupId": "OG001", "value": "268"}, {"groupId": "OG002", "value": "264"}]}], "classes": [{"title": "26 weeks (n=230, 237, 221)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.60", "spread": "0.60"}, {"groupId": "OG001", "value": "2.57", "spread": "0.59"}, {"groupId": "OG002", "value": "0.82", "spread": "0.61"}]}]}, {"title": "52 weeks (n=212, 212, 205)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.02", "spread": "0.66"}, {"groupId": "OG001", "value": "2.36", "spread": "0.66"}, {"groupId": "OG002", "value": "1.27", "spread": "0.67"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to 26 and 52 Weeks in Pulse Rate", "description": "Sitting pulse rate was measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, prior medication group, visit, and treatment-by-visit interaction as fixed effects, baseline interval as a covariate, and participant as a random effect.", "populationDescription": "Participants who received at least one dose of LY2189265 or Metformin with evaluable pulse rate data.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "beats per minute (bpm)", "timeFrame": "Baseline, 26 weeks, and 52 weeks", "groups": [{"id": "OG000", "title": "1.5 mg LY2189265", "description": "LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}, {"id": "OG001", "title": "0.75 mg LY2189265", "description": "LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}, {"id": "OG002", "title": "Metformin", "description": "Metformin: 2000 milligrams per day (mg/day) or at least 1500 mg/day, orally, for 52 weeks\n\nPlacebo: subcutaneously (SC), once weekly for 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "269"}, {"groupId": "OG001", "value": "270"}, {"groupId": "OG002", "value": "268"}]}], "classes": [{"title": "26 weeks (n=244, 251, 239)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.39", "spread": "0.58"}, {"groupId": "OG001", "value": "2.14", "spread": "0.57"}, {"groupId": "OG002", "value": "1.59", "spread": "0.58"}]}]}, {"title": "52 weeks (n=221, 219, 215)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.84", "spread": "0.57"}, {"groupId": "OG001", "value": "1.63", "spread": "0.57"}, {"groupId": "OG002", "value": "1.12", "spread": "0.57"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to 26 and 52 Weeks in Blood Pressure", "description": "Sitting systolic blood pressure (SBP) and sitting diastolic blood pressure (DBP) were measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, prior medication group, visit, and treatment-by-visit interaction as fixed effects, baseline interval as a covariate, and participant as a random effect.", "populationDescription": "Participants who received at least one dose of LY2189265 or Metformin with evaluable blood pressure data.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "milliliters of mercury (mmHg)", "timeFrame": "Baseline, 26 weeks, and 52 weeks", "groups": [{"id": "OG000", "title": "1.5 mg LY2189265", "description": "LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}, {"id": "OG001", "title": "0.75 mg LY2189265", "description": "LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}, {"id": "OG002", "title": "Metformin", "description": "Metformin: 2000 milligrams per day (mg/day) or at least 1500 mg/day, orally, for 52 weeks\n\nPlacebo: subcutaneously (SC), once weekly for 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "269"}, {"groupId": "OG001", "value": "270"}, {"groupId": "OG002", "value": "268"}]}], "classes": [{"title": "SBP, 26 weeks (n=244, 251, 239)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.89", "spread": "0.89"}, {"groupId": "OG001", "value": "-2.61", "spread": "0.88"}, {"groupId": "OG002", "value": "-0.91", "spread": "0.89"}]}]}, {"title": "SBP, 52 weeks (n=221, 219, 215)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.11", "spread": "0.88"}, {"groupId": "OG001", "value": "-2.74", "spread": "0.88"}, {"groupId": "OG002", "value": "-0.98", "spread": "0.88"}]}]}, {"title": "DBP, 26 weeks (n=244, 251, 239)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.05", "spread": "0.57"}, {"groupId": "OG001", "value": "-1.02", "spread": "0.56"}, {"groupId": "OG002", "value": "-0.64", "spread": "0.58"}]}]}, {"title": "DBP, 52 weeks (n=221, 219, 215)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.31", "spread": "0.60"}, {"groupId": "OG001", "value": "-1.37", "spread": "0.59"}, {"groupId": "OG002", "value": "-0.38", "spread": "0.60"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline to 26 and 52 Weeks in Total Cholesterol", "description": "Percent changes in total cholesterol were assessed using analysis of variance (ANOVA) on the rank-transformed data with only treatment included in the model.", "populationDescription": "Participants who received at least one dose of LY2189265 or Metformin with evaluable cholesterol data. Last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "percentage change in total cholesterol", "timeFrame": "Baseline, 26 weeks, and 52 weeks", "groups": [{"id": "OG000", "title": "1.5 mg LY2189265", "description": "LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}, {"id": "OG001", "title": "0.75 mg LY2189265", "description": "LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}, {"id": "OG002", "title": "Metformin", "description": "Metformin: 2000 milligrams per day (mg/day) or at least 1500 mg/day, orally, for 52 weeks\n\nPlacebo: subcutaneously (SC), once weekly for 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "258"}, {"groupId": "OG001", "value": "257"}, {"groupId": "OG002", "value": "256"}]}], "classes": [{"title": "26 weeks (n=244, 244, 243)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-3.86", "lowerLimit": "-10.83", "upperLimit": "5.24"}, {"groupId": "OG001", "value": "-1.77", "lowerLimit": "-9.78", "upperLimit": "7.57"}, {"groupId": "OG002", "value": "-3.51", "lowerLimit": "-12.19", "upperLimit": "5.45"}]}]}, {"title": "52 weeks (n=247, 248, 245)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.69", "lowerLimit": "-11.11", "upperLimit": "7.45"}, {"groupId": "OG001", "value": "-0.78", "lowerLimit": "-10.02", "upperLimit": "8.10"}, {"groupId": "OG002", "value": "-3.88", "lowerLimit": "-12.14", "upperLimit": "5.69"}]}]}]}, {"type": "SECONDARY", "title": "Percentage Change From Baseline to 26 and 52 Weeks in High Density Lipoprotein Cholesterol (HDL-C)", "description": "Percentage changes in HDL-C were assessed using analysis of variance (ANOVA) on the rank-transformed data with only treatment included in the model.", "populationDescription": "Participants who received at least one dose of LY2189265 or Metformin with evaluable HDL-C data. Last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "percentage change in HDL-C", "timeFrame": "Baseline, 26 weeks, and 52 weeks", "groups": [{"id": "OG000", "title": "1.5 mg LY2189265", "description": "LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}, {"id": "OG001", "title": "0.75 mg LY2189265", "description": "LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}, {"id": "OG002", "title": "Metformin", "description": "Metformin: 2000 milligrams per day (mg/day) or at least 1500 mg/day, orally, for 52 weeks\n\nPlacebo: subcutaneously (SC), once weekly for 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "259"}, {"groupId": "OG001", "value": "257"}, {"groupId": "OG002", "value": "257"}]}], "classes": [{"title": "26 weeks (n=246, 244, 244)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.39", "lowerLimit": "-4.11", "upperLimit": "13.54"}, {"groupId": "OG001", "value": "4.20", "lowerLimit": "-5.66", "upperLimit": "14.66"}, {"groupId": "OG002", "value": "5.78", "lowerLimit": "-2.66", "upperLimit": "14.13"}]}]}, {"title": "52 weeks (n=248, 248, 246)", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.95", "lowerLimit": "-4.55", "upperLimit": "13.17"}, {"groupId": "OG001", "value": "2.31", "lowerLimit": "-5.16", "upperLimit": "12.56"}, {"groupId": "OG002", "value": "4.32", "lowerLimit": "-6.56", "upperLimit": "13.64"}]}]}]}, {"type": "SECONDARY", "title": "Percentage Change From Baseline to 26 and 52 Weeks in Low Density Lipoprotein Cholesterol (LDL-C)", "description": "Percentage changes in LDL-C were assessed using analysis of variance (ANOVA) on the rank-transformed data with only treatment included in the model.", "populationDescription": "Participants who received at least one dose of LY2189265 or Metformin with evaluable LDL-C data. Last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "percentage change in LDL-C", "timeFrame": "Baseline, 26 weeks, and 52 weeks", "groups": [{"id": "OG000", "title": "1.5 mg LY2189265", "description": "LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}, {"id": "OG001", "title": "0.75 mg LY2189265", "description": "LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}, {"id": "OG002", "title": "Metformin", "description": "Metformin: 2000 milligrams per day (mg/day) or at least 1500 mg/day, orally, for 52 weeks\n\nPlacebo: subcutaneously (SC), once weekly for 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "249"}, {"groupId": "OG001", "value": "249"}, {"groupId": "OG002", "value": "243"}]}], "classes": [{"title": "26 weeks (n=233, 231, 221)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-6.86", "lowerLimit": "-18.26", "upperLimit": "8.20"}, {"groupId": "OG001", "value": "-2.70", "lowerLimit": "-15.33", "upperLimit": "9.15"}, {"groupId": "OG002", "value": "-8.97", "lowerLimit": "-20.21", "upperLimit": "5.00"}]}]}, {"title": "52 weeks (n=236, 240, 231)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.06", "lowerLimit": "-15.93", "upperLimit": "9.31"}, {"groupId": "OG001", "value": "-2.34", "lowerLimit": "-15.22", "upperLimit": "10.56"}, {"groupId": "OG002", "value": "-7.23", "lowerLimit": "-18.56", "upperLimit": "4.36"}]}]}]}, {"type": "SECONDARY", "title": "Percentage Change From Baseline to 26 and 52 Weeks in Triglycerides", "description": "Percentage changes in triglycerides were assessed using analysis of variance (ANOVA) on the rank-transformed data with only treatment included in the model.", "populationDescription": "Participants who received at least one dose of LY2189265 or Metformin with evaluable triglyceride data. Last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "percentage change in triglycerides", "timeFrame": "Baseline, 26 weeks, and 52 weeks", "groups": [{"id": "OG000", "title": "1.5 mg LY2189265", "description": "LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}, {"id": "OG001", "title": "0.75 mg LY2189265", "description": "LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}, {"id": "OG002", "title": "Metformin", "description": "Metformin: 2000 milligrams per day (mg/day) or at least 1500 mg/day, orally, for 52 weeks\n\nPlacebo: subcutaneously (SC), once weekly for 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "266"}, {"groupId": "OG001", "value": "265"}, {"groupId": "OG002", "value": "265"}]}], "classes": [{"title": "26 weeks (n=252, 252, 253)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.35", "lowerLimit": "-22.32", "upperLimit": "13.61"}, {"groupId": "OG001", "value": "-1.96", "lowerLimit": "-21.66", "upperLimit": "22.63"}, {"groupId": "OG002", "value": "2.56", "lowerLimit": "-16.00", "upperLimit": "23.79"}]}]}, {"title": "52 weeks (n=255, 256, 254)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-4.27", "lowerLimit": "-22.91", "upperLimit": "19.23"}, {"groupId": "OG001", "value": "-0.86", "lowerLimit": "-22.31", "upperLimit": "25.37"}, {"groupId": "OG002", "value": "1.91", "lowerLimit": "-21.65", "upperLimit": "24.04"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to 26 and 52 Weeks in Pancreatic Enzymes", "description": "Amylase (total and pancreas-derived \\[PD\\]) and lipase concentrations were measured.", "populationDescription": "Participants who received at least one dose of LY2189265 or Metformin with evaluable pancreatic enzyme data. Last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "units per liter (U/L)", "timeFrame": "Baseline, 26 weeks, and 52 weeks", "groups": [{"id": "OG000", "title": "1.5 mg LY2189265", "description": "LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}, {"id": "OG001", "title": "0.75 mg LY2189265", "description": "LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}, {"id": "OG002", "title": "Metformin", "description": "Metformin: 2000 milligrams per day (mg/day) or at least 1500 mg/day, orally, for 52 weeks\n\nPlacebo: subcutaneously (SC), once weekly for 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "266"}, {"groupId": "OG001", "value": "267"}, {"groupId": "OG002", "value": "267"}]}], "classes": [{"title": "Amylase (total), 26 weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "7.00", "lowerLimit": "2.00", "upperLimit": "13.00"}, {"groupId": "OG001", "value": "6.00", "lowerLimit": "0.00", "upperLimit": "13.00"}, {"groupId": "OG002", "value": "4.00", "lowerLimit": "-2.00", "upperLimit": "10.00"}]}]}, {"title": "Amylase (total), 52 weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "5.50", "lowerLimit": "-1.00", "upperLimit": "13.00"}, {"groupId": "OG001", "value": "5.00", "lowerLimit": "-1.00", "upperLimit": "13.00"}, {"groupId": "OG002", "value": "4.00", "lowerLimit": "-2.00", "upperLimit": "9.00"}]}]}, {"title": "Amylase (PD), 26 weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "5.00", "lowerLimit": "2.00", "upperLimit": "9.00"}, {"groupId": "OG001", "value": "4.00", "lowerLimit": "1.00", "upperLimit": "7.00"}, {"groupId": "OG002", "value": "1.00", "lowerLimit": "-1.00", "upperLimit": "5.00"}]}]}, {"title": "Amylase (PD), 52 weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.00", "lowerLimit": "1.00", "upperLimit": "7.00"}, {"groupId": "OG001", "value": "3.00", "lowerLimit": "0.00", "upperLimit": "8.00"}, {"groupId": "OG002", "value": "2.00", "lowerLimit": "-1.00", "upperLimit": "5.00"}]}]}, {"title": "Lipase, 26 weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "7.00", "lowerLimit": "1.00", "upperLimit": "16.00"}, {"groupId": "OG001", "value": "5.00", "lowerLimit": "0.00", "upperLimit": "13.00"}, {"groupId": "OG002", "value": "1.00", "lowerLimit": "-4.00", "upperLimit": "8.00"}]}]}, {"title": "Lipase, 52 weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "5.00", "lowerLimit": "-1.00", "upperLimit": "13.00"}, {"groupId": "OG001", "value": "5.00", "lowerLimit": "0.00", "upperLimit": "12.00"}, {"groupId": "OG002", "value": "1.00", "lowerLimit": "-4.00", "upperLimit": "6.00"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to 26 and 52 Weeks in Serum Calcitonin", "populationDescription": "Participants who received at least one dose of LY2189265 or Metformin with evaluable serum calcitonin data. Last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "picograms per milliliter (pcg/mL)", "timeFrame": "Baseline, 26 weeks, and 52 weeks", "groups": [{"id": "OG000", "title": "1.5 mg LY2189265", "description": "LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}, {"id": "OG001", "title": "0.75 mg LY2189265", "description": "LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}, {"id": "OG002", "title": "Metformin", "description": "Metformin: 2000 milligrams per day (mg/day) or at least 1500 mg/day, orally, for 52 weeks\n\nPlacebo: subcutaneously (SC), once weekly for 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "266"}, {"groupId": "OG001", "value": "267"}, {"groupId": "OG002", "value": "267"}]}], "classes": [{"title": "26 weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "0.00", "upperLimit": "0.00"}, {"groupId": "OG001", "value": "0.00", "lowerLimit": "0.00", "upperLimit": "0.00"}, {"groupId": "OG002", "value": "0.00", "lowerLimit": "0.00", "upperLimit": "0.00"}]}]}, {"title": "52 weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "0.00", "upperLimit": "0.00"}, {"groupId": "OG001", "value": "0.00", "lowerLimit": "0.00", "upperLimit": "0.00"}, {"groupId": "OG002", "value": "0.00", "lowerLimit": "0.00", "upperLimit": "0.00"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Treatment Emergent Anti-LY2189265 Antibodies", "description": "A participant was considered to have treatment emergent LY2189265 anti-drug antibodies (ADA) if the participant had at least one titer that was treatment-emergent relative to baseline, defined as a 4-fold or greater increase in titer from baseline measurement. The total number of treatment emergent ADA was not analyzed at 26 weeks.", "populationDescription": "Participants who received at least one dose of LY2189265 with evaluable LY2189265 ADA data.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline through 52 weeks", "groups": [{"id": "OG000", "title": "1.5 mg or 0.75 mg LY2189265", "description": "LY2189265 (Dulaglutide): 1.5 milligrams (mg) or 0.75 mg, subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "521"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "10"}]}]}]}, {"type": "SECONDARY", "title": "Number of Self-reported Hypoglycemic Events at 26 and 52 Weeks", "description": "Hypoglycemic events were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of less than or equal to 70 milligrams per deciliter \\[mg/dL\\]), or asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of less than or equal to 70 mg/dL). A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.", "populationDescription": "Participants who received at least one dose of LY2189265 or Metformin. Only pre-rescue measurements were used.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "events", "timeFrame": "Baseline through 26 weeks and 52 weeks", "groups": [{"id": "OG000", "title": "1.5 mg LY2189265", "description": "LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}, {"id": "OG001", "title": "0.75 mg LY2189265", "description": "LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}, {"id": "OG002", "title": "Metformin", "description": "Metformin: 2000 milligrams per day (mg/day) or at least 1500 mg/day, orally, for 52 weeks\n\nPlacebo: subcutaneously (SC), once weekly for 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "269"}, {"groupId": "OG001", "value": "270"}, {"groupId": "OG002", "value": "268"}]}], "classes": [{"title": "Severe, 26 weeks (n=241, 248, 236)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Severe, 52 weeks (n=214, 217, 199)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Documented Symptomatic, 26 weeks (n=241, 248, 236)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "6"}, {"groupId": "OG002", "value": "2"}]}]}, {"title": "Documented Symptomatic, 52 weeks (n=214, 217, 199)", "categories": [{"measurements": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "2"}]}]}, {"title": "Asymptomatic, 26 weeks (n=241, 248, 236)", "categories": [{"measurements": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "9"}, {"groupId": "OG002", "value": "13"}]}]}, {"title": "Asymptomatic, 52 weeks (n=214, 217, 199)", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "9"}, {"groupId": "OG002", "value": "9"}]}]}]}, {"type": "SECONDARY", "title": "Rate of Self-reported Hypoglycemic Events at 52 Weeks", "description": "Hypoglycemic events were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of less than or equal to 70 milligrams per deciliter \\[mg/dL\\]), or asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of less than or equal to 70 mg/dL). The 1-year adjusted rate of hypoglycemic events is summarized cumulatively at 52 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.", "populationDescription": "Participants who received at least one dose of LY2189265 or Metformin. Only pre-rescue measurements were used.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "events per participant per year", "timeFrame": "Baseline through 52 weeks", "groups": [{"id": "OG000", "title": "1.5 mg LY2189265", "description": "LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}, {"id": "OG001", "title": "0.75 mg LY2189265", "description": "LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}, {"id": "OG002", "title": "Metformin", "description": "Metformin: 2000 milligrams per day (mg/day) or at least 1500 mg/day, orally, for 52 weeks\n\nPlacebo: subcutaneously (SC), once weekly for 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "269"}, {"groupId": "OG001", "value": "270"}, {"groupId": "OG002", "value": "268"}]}], "classes": [{"title": "Severe", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "spread": "0.00"}, {"groupId": "OG001", "value": "0.00", "spread": "0.00"}, {"groupId": "OG002", "value": "0.00", "spread": "0.00"}]}]}, {"title": "Documented Symptomatic", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.62", "spread": "8.91"}, {"groupId": "OG001", "value": "0.15", "spread": "0.72"}, {"groupId": "OG002", "value": "0.09", "spread": "0.50"}]}]}, {"title": "Asymptomatic", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.24", "spread": "1.26"}, {"groupId": "OG001", "value": "0.30", "spread": "1.85"}, {"groupId": "OG002", "value": "0.18", "spread": "0.79"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Adjudicated Pancreatitis at 52 Weeks Plus 30-day Follow up", "description": "The number of participants with pancreatitis confirmed by adjudication is summarized cumulatively at 52 weeks plus 30-day follow up. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.", "populationDescription": "Participants who received at least one dose of LY2189265 or Metformin. Only pre-rescue measurements were used.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline through 52 weeks plus 30-day follow up", "groups": [{"id": "OG000", "title": "1.5 mg LY2189265", "description": "LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}, {"id": "OG001", "title": "0.75 mg LY2189265", "description": "LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}, {"id": "OG002", "title": "Metformin", "description": "Metformin: 2000 milligrams per day (mg/day) or at least 1500 mg/day, orally, for 52 weeks\n\nPlacebo: subcutaneously (SC), once weekly for 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "269"}, {"groupId": "OG001", "value": "270"}, {"groupId": "OG002", "value": "268"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Adjudicated Cardiovascular Events at 52 Weeks Plus 30-day Follow up", "description": "Information on cardiovascular (CV) risk factors was collected at baseline. Data on any new CV event was prospectively collected using a CV event electronic case report form. Deaths and nonfatal cardiovascular adverse events (AEs) were adjudicated by an external committee of physicians with cardiology expertise. Nonfatal cardiovascular AEs to be adjudicated included myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions, and cerebrovascular events, including cerebrovascular accident (stroke) and transient ischemic attack. The number of participants with CV events confirmed by adjudication is summarized cumulatively at 52 weeks plus 30-day follow up. Serious and all other non-serious adverse events regardless of causality are summarized in the Reported Adverse Events module.", "populationDescription": "Participants who received at least one dose of LY2189265 or Metformin.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline through 52 weeks plus 30-day follow up", "groups": [{"id": "OG000", "title": "1.5 mg LY2189265", "description": "LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}, {"id": "OG001", "title": "0.75 mg LY2189265", "description": "LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}, {"id": "OG002", "title": "Metformin", "description": "Metformin: 2000 milligrams per day (mg/day) or at least 1500 mg/day, orally, for 52 weeks\n\nPlacebo: subcutaneously (SC), once weekly for 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "269"}, {"groupId": "OG001", "value": "270"}, {"groupId": "OG002", "value": "268"}]}], "classes": [{"title": "Any CV Event", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "1"}]}]}, {"title": "Any Fatal CV Event", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Any Nonfatal CV Event", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "1"}]}]}]}, {"type": "SECONDARY", "title": "Measurement of LY2189265 Drug Concentration for Pharmacokinetics: Area Under the Concentration Curve (AUC)", "description": "Evaluable pharmacokinetic concentrations from the 4-week, 13-week, 26-week, and 52-week timepoints were combined and utilized in a population approach to determine the population mean estimate and standard deviation at steady-state.", "populationDescription": "Participants who received at least one dose of LY2189265 with evaluable LY2189265 concentration data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "nanogram hours per milliliter (ng*hr/mL)", "timeFrame": "4 weeks, 13 weeks, 26 weeks, and 52 weeks", "groups": [{"id": "OG000", "title": "1.5 mg LY2189265", "description": "LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}, {"id": "OG001", "title": "0.75 mg LY2189265", "description": "LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "144"}, {"groupId": "OG001", "value": "146"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "12036", "spread": "5385"}, {"groupId": "OG001", "value": "5919", "spread": "1548"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "4", "eventGroups": [{"id": "EG000", "title": "1.5 mg LY2189265", "description": "LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks", "seriousNumAffected": 15, "seriousNumAtRisk": 269, "otherNumAffected": 177, "otherNumAtRisk": 269}, {"id": "EG001", "title": "0.75 mg LY2189265", "description": "LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks\n\nPlacebo: orally, twice daily for 52 weeks", "seriousNumAffected": 20, "seriousNumAtRisk": 270, "otherNumAffected": 178, "otherNumAtRisk": 270}, {"id": "EG002", "title": "Metformin", "description": "Metformin: 2000 milligrams per day (mg/day) or at least 1500 mg/day, orally, for 52 weeks\n\nPlacebo: subcutaneously (SC), once weekly for 52 weeks", "seriousNumAffected": 16, "seriousNumAtRisk": 268, "otherNumAffected": 170, "otherNumAtRisk": 268}], "seriousEvents": [{"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 268}]}, {"term": "Angina pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 268}]}, {"term": "Angina unstable", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 268}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 268}]}, {"term": "Cardiac failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 268}]}, {"term": "Cardiac failure congestive", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 2, "numAffected": 1, "numAtRisk": 268}]}, {"term": "Coronary artery stenosis", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 268}]}, {"term": "Pericardial effusion", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 268}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 268}]}, {"term": "Colitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 268}]}, {"term": "Constipation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 268}]}, {"term": "Diarrhoea haemorrhagic", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 268}]}, {"term": "Dysphagia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 268}]}, {"term": "Hiatus hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 268}]}, {"term": "Ileus", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 268}]}, {"term": "Oesophageal spasm", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 268}]}, {"term": "Chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 268}]}, {"term": "Paradoxical drug reaction", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 268}]}, {"term": "Cholecystitis acute", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 268}]}, {"term": "Cholecystitis chronic", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 268}]}, {"term": "Cholelithiasis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 268}]}, {"term": "Gallbladder disorder", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 268}]}, {"term": "Abdominal abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 268}]}, {"term": "Appendicitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 268}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 268}]}, {"term": "Cholecystitis infective", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 268}]}, {"term": "Disseminated tuberculosis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 268}]}, {"term": "Echinococciasis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 268}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 268}]}, {"term": "Hepatic echinococciasis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 268}]}, {"term": "Pharyngeal abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 268}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 268}]}, {"term": "Pyelonephritis acute", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 268}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 268}]}, {"term": "Alcohol poisoning", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 268}]}, {"term": "Fall", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 268}]}, {"term": "Humerus fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 268}]}, {"term": "Meniscus lesion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 268}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 268}]}, {"term": "Intervertebral disc protrusion", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 268}]}, {"term": "Musculoskeletal chest pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 268}]}, {"term": "Osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 268}]}, {"term": "Osteonecrosis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 268}]}, {"term": "Spinal column stenosis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 268}]}, {"term": "Non-hodgkin's lymphoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 268}]}, {"term": "Ovarian fibroma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 155}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 152}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 147}]}, {"term": "Tongue carcinoma stage I", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 268}]}, {"term": "Cerebral infarction", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 268}]}, {"term": "Convulsion", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 268}]}, {"term": "Hypoaesthesia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 268}]}, {"term": "Presyncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 268}]}, {"term": "Syncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 268}]}, {"term": "Transient ischaemic attack", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 268}]}, {"term": "VIth nerve paralysis", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 268}]}, {"term": "Pregnancy", "organSystem": "Pregnancy, puerperium and perinatal conditions", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 155}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 152}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 147}]}, {"term": "Bipolar II disorder", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 2, "numAffected": 1, "numAtRisk": 268}]}, {"term": "Suicidal ideation", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 268}]}, {"term": "Nephrolithiasis", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 268}]}, {"term": "Bronchospasm", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 2, "numAffected": 1, "numAtRisk": 268}]}, {"term": "Haemoptysis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 268}]}, {"term": "Nasal polyps", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 268}]}, {"term": "Nasal septum deviation", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 268}]}, {"term": "Nasal turbinate hypertrophy", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 268}]}, {"term": "Pleural effusion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 268}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 268}]}], "otherEvents": [{"term": "Abdominal distension", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 18, "numAffected": 13, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 19, "numAffected": 13, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 14, "numAffected": 10, "numAtRisk": 268}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 16, "numAffected": 11, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 11, "numAffected": 10, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 7, "numAffected": 6, "numAtRisk": 268}]}, {"term": "Constipation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 23, "numAffected": 18, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 13, "numAffected": 12, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 268}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 37, "numAffected": 31, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 30, "numAffected": 26, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 44, "numAffected": 39, "numAtRisk": 268}]}, {"term": "Dyspepsia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 15, "numAffected": 12, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 22, "numAffected": 8, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 7, "numAffected": 6, "numAtRisk": 268}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 76, "numAffected": 53, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 45, "numAffected": 31, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 50, "numAffected": 43, "numAtRisk": 268}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 32, "numAffected": 26, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 24, "numAffected": 20, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 70, "numAffected": 14, "numAtRisk": 268}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 8, "numAffected": 7, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 11, "numAffected": 11, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 9, "numAffected": 9, "numAtRisk": 268}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 11, "numAffected": 9, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 14, "numAffected": 11, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 13, "numAffected": 8, "numAtRisk": 268}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 16, "numAffected": 14, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 10, "numAffected": 9, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 39, "numAffected": 28, "numAtRisk": 268}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 16, "numAffected": 16, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 20, "numAffected": 17, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 10, "numAffected": 8, "numAtRisk": 268}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 11, "numAffected": 10, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 13, "numAffected": 11, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 7, "numAffected": 6, "numAtRisk": 268}]}, {"term": "Decreased appetite", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 22, "numAffected": 18, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 15, "numAffected": 12, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 14, "numAffected": 12, "numAtRisk": 268}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 5, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 11, "numAffected": 9, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 13, "numAffected": 12, "numAtRisk": 268}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 5, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 13, "numAffected": 12, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 12, "numAffected": 9, "numAtRisk": 268}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 14, "numAffected": 10, "numAtRisk": 269}, {"groupId": "EG001", "numEvents": 57, "numAffected": 14, "numAtRisk": 270}, {"groupId": "EG002", "numEvents": 28, "numAffected": 20, "numAtRisk": 268}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "GT60", "restrictiveAgreement": true}, "pointOfContact": {"title": "Chief Medical Officer", "organization": "Eli Lilly and Company", "phone": "800-545-5979"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Diabetes Mellitus, Type 2", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "C000555680", "term": "Dulaglutide"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000097789", "term": "Glucagon-Like Peptide-1 Receptor Agonists"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M258626", "name": "Dulaglutide", "asFound": "Clostridium", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M3401", "name": "Glucagon-Like Peptide-1 Receptor Agonists", "relevance": "LOW"}, {"id": "M9043", "name": "Glucagon", "relevance": "LOW"}, {"id": "M26997", "name": "Glucagon-Like Peptide 1", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Gast", "name": "Gastrointestinal Agents"}]}}, "hasResults": true}